Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
1500003O 03Rik | |
NM_019769 |
RIKEN cDNA 1500003O03 gene (1500003O03Rik), mRNA [NM_019769] |
KLA | .92 |
.89 |
.89 |
.86 |
.85 |
.92 |
1.08 |
| ATP | 1.01 |
1.16 |
1.16 |
1.53 |
1.70 |
3.33 |
2.09 |
| KLA/ATP | .89 |
.97 |
.93 |
1.17 |
1.19 |
2.86 |
2.57 |
|
2010110P 09Rik | |
NM_027363 |
RIKEN cDNA 2010110P09 gene (2010110P09Rik), mRNA [NM_027363] |
KLA | .99 |
.98 |
1.02 |
.99 |
.94 |
1.01 |
1.01 |
| ATP | 1.04 |
1.05 |
.97 |
1.05 |
.95 |
.98 |
.95 |
| KLA/ATP | .93 |
1.00 |
1.02 |
.97 |
1.01 |
.96 |
.97 |
|
AK036998
| |
AK036998 |
adult female vagina cDNA, RIKEN full-length enriched library, clone:9930034M05 product:unclassifiable, full insert sequence. [AK036998] |
KLA | 1.43 |
1.09 |
.89 |
.79 |
.96 |
.97 |
.71 |
| ATP | 1.04 |
1.04 |
.71 |
.64 |
.90 |
.82 |
.82 |
| KLA/ATP | 1.34 |
1.23 |
1.01 |
.89 |
1.10 |
.82 |
.75 |
|
AK043675
| |
AK043675 |
10 days neonate cortex cDNA, RIKEN full-length enriched library, clone:A830019B06 product:unclassifiable, full insert sequence. [AK043675] |
KLA | 1.07 |
1.05 |
1.00 |
.98 |
1.05 |
1.02 |
1.00 |
| ATP | .92 |
1.07 |
.99 |
.93 |
1.01 |
1.01 |
1.02 |
| KLA/ATP | .96 |
.93 |
1.08 |
1.00 |
.94 |
.97 |
1.02 |
|
AK045358
| |
AK045358 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230105H23 product:voltage-dependent anion channel 3, full insert sequence [AK045358] |
KLA | .96 |
.98 |
.96 |
.96 |
1.02 |
1.03 |
1.01 |
| ATP | .97 |
.95 |
1.01 |
.99 |
1.08 |
1.01 |
.97 |
| KLA/ATP | .99 |
.99 |
.98 |
1.01 |
.99 |
1.06 |
.99 |
|
Adcy1 | |
BC050125 |
adenylate cyclase 1, mRNA (cDNA clone IMAGE:30015692). [BC050125] |
KLA | 1.05 |
1.03 |
.98 |
1.04 |
1.05 |
1.09 |
1.10 |
| ATP | .90 |
1.02 |
.99 |
.97 |
1.03 |
.95 |
1.01 |
| KLA/ATP | .99 |
1.04 |
.90 |
.98 |
.98 |
1.00 |
1.03 |
|
Adcy1 | |
NM_009622 |
adenylate cyclase 1 (Adcy1), mRNA [NM_009622] |
KLA | 1.07 |
1.02 |
1.06 |
1.07 |
1.03 |
1.02 |
1.01 |
| ATP | 1.02 |
1.04 |
1.00 |
.99 |
.99 |
.95 |
.97 |
| KLA/ATP | .97 |
1.05 |
1.02 |
1.05 |
1.01 |
.98 |
1.05 |
|
Adcy2 | |
NM_153534 |
adenylate cyclase 2 (Adcy2), mRNA [NM_153534] |
KLA | .79 |
.82 |
.83 |
.73 |
.61 |
.66 |
.90 |
| ATP | 1.10 |
1.09 |
1.02 |
1.04 |
.88 |
.58 |
.53 |
| KLA/ATP | .84 |
.87 |
.77 |
.75 |
.68 |
.60 |
.43 |
|
Adcy3 | |
NM_138305 |
adenylate cyclase 3 (Adcy3), mRNA [NM_138305] |
KLA | .84 |
.84 |
.83 |
.78 |
.66 |
.55 |
.49 |
| ATP | 1.09 |
1.05 |
.89 |
1.02 |
.84 |
.62 |
1.52 |
| KLA/ATP | .93 |
.87 |
.75 |
.85 |
.66 |
.83 |
.77 |
|
Adcy4 | |
NM_080435 |
adenylate cyclase 4 (Adcy4), mRNA [NM_080435] |
KLA | 1.05 |
1.07 |
.96 |
1.00 |
1.04 |
1.05 |
1.05 |
| ATP | 1.02 |
1.05 |
1.02 |
1.48 |
1.37 |
1.08 |
1.09 |
| KLA/ATP | 1.00 |
1.05 |
.91 |
1.19 |
1.35 |
1.27 |
1.08 |
|
Adcy7 | |
NM_001037724 |
adenylate cyclase 7 (Adcy7), transcript variant 3, mRNA [NM_001037724] |
KLA | .43 |
.39 |
.35 |
.32 |
.45 |
.72 |
.84 |
| ATP | .90 |
.84 |
.62 |
.41 |
.53 |
.42 |
.94 |
| KLA/ATP | .39 |
.34 |
.23 |
.17 |
.41 |
.34 |
.67 |
|
Adcy7 | |
NM_007406 |
adenylate cyclase 7 (Adcy7), transcript variant 1, mRNA [NM_007406] |
KLA | .51 |
.52 |
.48 |
.41 |
.59 |
.81 |
.99 |
| ATP | 1.01 |
1.02 |
.62 |
.52 |
.53 |
.38 |
.98 |
| KLA/ATP | .53 |
.48 |
.30 |
.27 |
.42 |
.36 |
.65 |
|
Adcy8 | |
NM_009623 |
adenylate cyclase 8 (Adcy8), mRNA [NM_009623] |
KLA | 1.00 |
1.00 |
1.07 |
.97 |
1.04 |
.98 |
1.02 |
| ATP | 1.04 |
1.05 |
1.14 |
1.03 |
.99 |
1.00 |
.97 |
| KLA/ATP | 1.05 |
1.04 |
1.00 |
1.03 |
.98 |
.94 |
.96 |
|
Adcy9 | |
NM_009624 |
adenylate cyclase 9 (Adcy9), mRNA [NM_009624] |
KLA | .18 |
.15 |
.13 |
.15 |
.17 |
.19 |
.33 |
| ATP | 1.33 |
1.16 |
.97 |
.98 |
.62 |
.56 |
.86 |
| KLA/ATP | .19 |
.16 |
.17 |
.18 |
.20 |
.25 |
.38 |
|
Adora2a | |
NM_009630 |
adenosine A2a receptor (Adora2a), mRNA [NM_009630] |
KLA | 9.23 |
9.88 |
9.08 |
9.21 |
9.36 |
7.45 |
8.23 |
| ATP | 1.09 |
1.01 |
1.36 |
2.05 |
4.26 |
8.29 |
1.91 |
| KLA/ATP | 9.17 |
11.00 |
9.06 |
9.28 |
10.88 |
11.46 |
9.73 |
|
Adora2b | |
NM_007413 |
adenosine A2b receptor (Adora2b), mRNA [NM_007413] |
KLA | 2.50 |
3.09 |
4.71 |
7.11 |
7.38 |
4.18 |
3.17 |
| ATP | .98 |
1.02 |
1.16 |
4.52 |
8.81 |
7.95 |
2.66 |
| KLA/ATP | 2.56 |
3.38 |
4.49 |
5.78 |
7.34 |
7.41 |
6.23 |
|
Adra1a | |
NM_013461 |
adrenergic receptor, alpha 1a (Adra1a), mRNA [NM_013461] |
KLA | .78 |
.74 |
.75 |
.85 |
.96 |
1.37 |
2.70 |
| ATP | 1.05 |
1.14 |
.97 |
.97 |
1.69 |
1.06 |
2.56 |
| KLA/ATP | .76 |
.75 |
.83 |
.84 |
1.51 |
1.34 |
4.08 |
|
Adra1b | |
NM_007416 |
adrenergic receptor, alpha 1b (Adra1b), mRNA [NM_007416] |
KLA | 1.04 |
.99 |
.98 |
1.02 |
.99 |
1.00 |
1.01 |
| ATP | 1.00 |
.99 |
.98 |
1.01 |
1.06 |
1.01 |
1.05 |
| KLA/ATP | .99 |
.97 |
1.03 |
1.03 |
1.00 |
.97 |
1.08 |
|
Adra1d | |
NM_013460 |
adrenergic receptor, alpha 1d (Adra1d), mRNA [NM_013460] |
KLA | 1.13 |
1.12 |
1.21 |
1.25 |
1.30 |
1.34 |
1.27 |
| ATP | 1.02 |
.99 |
1.16 |
1.08 |
1.13 |
1.11 |
1.06 |
| KLA/ATP | 1.15 |
1.10 |
1.20 |
1.14 |
1.24 |
1.16 |
1.13 |
|
Adrb1 | |
NM_007419 |
adrenergic receptor, beta 1 (Adrb1), mRNA [NM_007419] |
KLA | .88 |
.86 |
.88 |
.86 |
.87 |
.87 |
.87 |
| ATP | .97 |
.97 |
.95 |
.89 |
.89 |
.90 |
.87 |
| KLA/ATP | .90 |
.88 |
.91 |
.84 |
.91 |
.79 |
.82 |
|
Adrb2 | |
NM_007420 |
adrenergic receptor, beta 2 (Adrb2), mRNA [NM_007420] |
KLA | .28 |
.26 |
.32 |
.31 |
.34 |
.31 |
.29 |
| ATP | 2.09 |
2.43 |
2.74 |
1.72 |
.96 |
.63 |
.29 |
| KLA/ATP | .28 |
.29 |
.52 |
.69 |
.65 |
.35 |
.23 |
|
Agtr1a | |
NM_177322 |
angiotensin II receptor, type 1a (Agtr1a), mRNA [NM_177322] |
KLA | 1.04 |
1.00 |
1.00 |
1.03 |
1.03 |
.95 |
1.00 |
| ATP | .98 |
.99 |
1.00 |
1.00 |
.95 |
1.05 |
1.06 |
| KLA/ATP | 1.00 |
.97 |
1.03 |
.97 |
.99 |
.96 |
.98 |
|
Agtr1b | |
NM_175086 |
angiotensin II receptor, type 1b (Agtr1b), mRNA [NM_175086] |
KLA | 1.02 |
.94 |
1.04 |
1.01 |
1.01 |
1.00 |
.95 |
| ATP | .97 |
1.01 |
1.03 |
.95 |
.98 |
1.09 |
1.02 |
| KLA/ATP | .94 |
.99 |
.99 |
.97 |
.99 |
.95 |
1.12 |
|
Atp2a1 | |
NM_007504 |
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 (Atp2a1), mRNA [NM_007504] |
KLA | 1.05 |
1.05 |
1.02 |
.99 |
1.04 |
1.07 |
1.27 |
| ATP | 1.02 |
1.13 |
.96 |
1.13 |
1.10 |
1.17 |
1.12 |
| KLA/ATP | 1.15 |
1.11 |
.90 |
1.12 |
.93 |
1.14 |
.99 |
|
Atp2a2 | |
NM_001110140 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 (Atp2a2), transcript variant 1, mRNA [NM_001110140] |
KLA | .95 |
1.07 |
.96 |
.84 |
1.17 |
1.16 |
1.53 |
| ATP | 1.16 |
1.27 |
.80 |
1.14 |
1.10 |
1.23 |
1.35 |
| KLA/ATP | 1.14 |
1.10 |
.54 |
1.15 |
.91 |
1.10 |
1.01 |
|
Atp2a2 | |
NM_009722 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 (Atp2a2), transcript variant 2, mRNA [NM_009722] |
KLA | .90 |
.90 |
.99 |
.96 |
1.28 |
1.09 |
1.29 |
| ATP | 1.09 |
1.12 |
.94 |
1.19 |
1.47 |
1.36 |
.98 |
| KLA/ATP | .98 |
.95 |
.72 |
1.06 |
1.44 |
1.30 |
.88 |
|
Atp2a3 | |
NM_016745 |
ATPase, Ca++ transporting, ubiquitous (Atp2a3), mRNA [NM_016745] |
KLA | 1.10 |
1.12 |
1.17 |
1.14 |
.99 |
.85 |
.54 |
| ATP | 1.05 |
1.11 |
1.15 |
1.32 |
1.14 |
1.00 |
.60 |
| KLA/ATP | 1.21 |
1.22 |
1.31 |
1.26 |
1.05 |
.88 |
.63 |
|
Atp2b1 | |
AK053569 |
0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130111D10 product:unclassifiable, full insert sequence. [AK053569] |
KLA | 1.18 |
1.02 |
.86 |
.87 |
.88 |
.99 |
.97 |
| ATP | 1.38 |
1.60 |
8.03 |
2.45 |
1.66 |
1.16 |
.94 |
| KLA/ATP | 1.32 |
1.41 |
6.67 |
1.98 |
1.15 |
1.08 |
.96 |
|
Atp2b1 | |
AK161995 |
12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720440F18 product:Plasma membrane calcium pump isoform 1b (Fragment) homolog [Canis familiaris], full insert sequence. [AK16199 |
KLA | 1.64 |
1.50 |
1.23 |
1.02 |
.71 |
.75 |
.92 |
| ATP | 1.04 |
1.12 |
1.69 |
1.64 |
1.34 |
1.03 |
.66 |
| KLA/ATP | 1.69 |
1.58 |
2.20 |
1.99 |
1.03 |
.67 |
.57 |
|
Atp2b1 | |
NM_026482 |
ATPase, Ca++ transporting, plasma membrane 1 (Atp2b1), mRNA [NM_026482] |
KLA | 1.91 |
1.76 |
1.64 |
1.21 |
.84 |
.79 |
1.07 |
| ATP | 1.00 |
1.01 |
1.43 |
2.32 |
2.28 |
1.71 |
1.06 |
| KLA/ATP | 1.86 |
1.85 |
2.23 |
2.48 |
1.71 |
1.05 |
1.04 |
|
Atp2b2 | |
NM_009723 |
ATPase, Ca++ transporting, plasma membrane 2 (Atp2b2), transcript variant 1, mRNA [NM_009723] |
KLA | 1.02 |
.93 |
1.01 |
1.01 |
1.04 |
1.00 |
1.09 |
| ATP | 1.00 |
1.03 |
1.01 |
1.05 |
1.05 |
1.04 |
.90 |
| KLA/ATP | .99 |
.95 |
1.04 |
1.06 |
1.01 |
.99 |
1.00 |
|
Atp2b3 | |
AK032322 |
adult male olfactory brain cDNA, RIKEN full-length enriched library, clone:6430519O13 product:PLASMA MEMBRANE CALCIUM-TRANSPORTING ATPASE 3 (EC 3.6.3.8) (PMCA3) (PLASMA MEMBRANE CALCIUM PUMP ISOFORM 3) (PLASMA MEMBRANE CALCIUM ATPASE ISOF |
KLA | 1.00 |
1.05 |
1.01 |
1.09 |
1.00 |
1.04 |
1.09 |
| ATP | 1.02 |
.97 |
1.01 |
1.12 |
.95 |
1.19 |
1.16 |
| KLA/ATP | 1.01 |
.95 |
.97 |
1.09 |
1.12 |
1.06 |
1.14 |
|
Avpr1a | |
NM_016847 |
arginine vasopressin receptor 1A (Avpr1a), mRNA [NM_016847] |
KLA | 1.00 |
1.07 |
.95 |
.99 |
1.01 |
1.01 |
1.00 |
| ATP | .99 |
.94 |
1.01 |
1.08 |
1.01 |
1.06 |
.99 |
| KLA/ATP | 1.10 |
.98 |
1.04 |
1.00 |
.99 |
1.05 |
1.00 |
|
Avpr1b | |
NM_011924 |
arginine vasopressin receptor 1B (Avpr1b), mRNA [NM_011924] |
KLA | 1.01 |
.93 |
.97 |
1.03 |
1.00 |
.97 |
1.01 |
| ATP | .99 |
1.02 |
1.05 |
1.03 |
1.01 |
1.04 |
1.06 |
| KLA/ATP | .93 |
1.00 |
.97 |
.97 |
.92 |
.96 |
1.04 |
|
Bdkrb1 | |
NM_007539 |
bradykinin receptor, beta 1 (Bdkrb1), mRNA [NM_007539] |
KLA | 1.60 |
1.44 |
1.47 |
1.36 |
1.29 |
1.38 |
1.04 |
| ATP | 1.05 |
.99 |
1.17 |
1.12 |
1.15 |
1.16 |
.95 |
| KLA/ATP | 1.51 |
1.59 |
1.94 |
1.30 |
1.22 |
1.23 |
1.20 |
|
Bdkrb2 | |
NM_009747 |
bradykinin receptor, beta 2 (Bdkrb2), mRNA [NM_009747] |
KLA | .97 |
.96 |
1.01 |
1.09 |
1.01 |
1.00 |
1.08 |
| ATP | 1.07 |
.98 |
1.04 |
1.01 |
1.05 |
1.00 |
1.08 |
| KLA/ATP | 1.02 |
1.05 |
1.04 |
1.01 |
1.03 |
1.04 |
.98 |
|
Bst1 | |
NM_009763 |
bone marrow stromal cell antigen 1 (Bst1), mRNA [NM_009763] |
KLA | 2.26 |
2.15 |
2.90 |
3.73 |
4.89 |
5.96 |
6.57 |
| ATP | 1.05 |
1.06 |
1.31 |
1.52 |
1.57 |
4.31 |
4.76 |
| KLA/ATP | 2.29 |
2.31 |
3.10 |
2.98 |
3.09 |
5.35 |
13.91 |
|
Cacna1a | |
NM_007578 |
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (Cacna1a), mRNA [NM_007578] |
KLA | .71 |
.66 |
.61 |
.63 |
.60 |
.71 |
.72 |
| ATP | 1.07 |
1.04 |
.89 |
1.08 |
.71 |
.56 |
.75 |
| KLA/ATP | .71 |
.72 |
.85 |
.69 |
.64 |
.63 |
.68 |
|
Cacna1b | |
U04999 |
N-type calcium channel alpha1 subunit mRNA, complete cds [U04999] |
KLA | .94 |
.94 |
.95 |
.88 |
1.09 |
.85 |
.92 |
| ATP | 1.06 |
1.17 |
1.00 |
1.24 |
1.59 |
1.15 |
1.17 |
| KLA/ATP | .91 |
.91 |
.95 |
.95 |
.90 |
.97 |
1.01 |
|
Cacna1d | |
NM_001083616 |
calcium channel, voltage-dependent, L type, alpha 1D subunit (Cacna1d), transcript variant 2, mRNA [NM_001083616] |
KLA | 1.57 |
1.58 |
2.50 |
3.62 |
4.55 |
2.93 |
.99 |
| ATP | 1.12 |
.99 |
.97 |
.94 |
.75 |
1.71 |
1.48 |
| KLA/ATP | 1.47 |
1.51 |
1.82 |
1.56 |
1.67 |
2.93 |
4.60 |
|
Cacna1d | |
NM_028981 |
calcium channel, voltage-dependent, L type, alpha 1D subunit (Cacna1d), transcript variant 1, mRNA [NM_028981] |
KLA | 1.20 |
1.26 |
1.43 |
1.62 |
2.07 |
1.66 |
1.00 |
| ATP | 1.03 |
1.03 |
.97 |
.97 |
.93 |
1.20 |
1.26 |
| KLA/ATP | 1.16 |
1.12 |
1.10 |
1.14 |
1.08 |
1.44 |
2.56 |
|
Cacna1e | |
NM_009782 |
calcium channel, voltage-dependent, R type, alpha 1E subunit (Cacna1e), mRNA [NM_009782] |
KLA | 1.01 |
.96 |
1.00 |
1.00 |
1.02 |
.99 |
1.04 |
| ATP | 1.03 |
.96 |
.95 |
1.01 |
1.02 |
1.02 |
1.00 |
| KLA/ATP | 1.01 |
1.01 |
1.00 |
1.04 |
.97 |
1.03 |
1.00 |
|
Cacna1f | |
NM_019582 |
calcium channel, voltage-dependent, alpha 1F subunit (Cacna1f), mRNA [NM_019582] |
KLA | 1.03 |
.98 |
1.05 |
1.06 |
1.00 |
1.02 |
1.01 |
| ATP | 1.05 |
1.05 |
.95 |
.98 |
.97 |
.96 |
1.01 |
| KLA/ATP | 1.01 |
1.03 |
.94 |
1.01 |
1.01 |
1.00 |
.99 |
|
Cacna1g | |
NM_009783 |
calcium channel, voltage-dependent, T type, alpha 1G subunit (Cacna1g), transcript variant 1, mRNA [NM_009783] |
KLA | .98 |
.96 |
.95 |
1.02 |
.99 |
1.03 |
1.01 |
| ATP | .95 |
.98 |
1.03 |
1.00 |
1.01 |
1.01 |
1.01 |
| KLA/ATP | 1.00 |
.97 |
.93 |
.99 |
.94 |
1.00 |
1.06 |
|
Cacna1h | |
NM_021415 |
calcium channel, voltage-dependent, T type, alpha 1H subunit (Cacna1h), mRNA [NM_021415] |
KLA | 1.07 |
1.00 |
1.04 |
1.01 |
1.02 |
.98 |
1.06 |
| ATP | .97 |
.96 |
1.05 |
1.00 |
1.00 |
.96 |
.99 |
| KLA/ATP | 1.00 |
.99 |
.96 |
.98 |
.96 |
.97 |
.92 |
|
Cacna1i | |
NM_001044308 |
calcium channel, voltage-dependent, alpha 1I subunit (Cacna1i), mRNA [NM_001044308] |
KLA | 1.02 |
.96 |
1.01 |
.98 |
1.00 |
1.05 |
.90 |
| ATP | .98 |
1.00 |
1.05 |
.98 |
1.04 |
.95 |
.99 |
| KLA/ATP | .97 |
.94 |
1.02 |
1.03 |
1.03 |
1.03 |
1.01 |
|
Cacna1s | |
NM_001081023 |
calcium channel, voltage-dependent, L type, alpha 1S subunit (Cacna1s), mRNA [NM_001081023] |
KLA | 1.03 |
1.01 |
.96 |
1.06 |
1.00 |
1.00 |
1.05 |
| ATP | 1.01 |
.98 |
1.02 |
1.02 |
1.05 |
1.07 |
1.05 |
| KLA/ATP | .99 |
1.05 |
1.02 |
1.05 |
1.03 |
1.05 |
1.00 |
|
Calm1 | |
NM_009790 |
calmodulin 1 (Calm1), mRNA [NM_009790] |
KLA | 1.20 |
1.26 |
1.30 |
1.06 |
1.16 |
1.09 |
1.18 |
| ATP | 1.07 |
1.20 |
1.00 |
1.29 |
.99 |
.64 |
.58 |
| KLA/ATP | 1.31 |
1.31 |
.93 |
1.31 |
.97 |
.83 |
.59 |
|
Calm2 | |
NM_007589 |
calmodulin 2 (Calm2), mRNA [NM_007589] |
KLA | .79 |
.81 |
.71 |
.67 |
.54 |
.45 |
.64 |
| ATP | .99 |
1.03 |
1.04 |
.93 |
.82 |
.52 |
.76 |
| KLA/ATP | .76 |
.78 |
.76 |
.77 |
.73 |
.47 |
.42 |
|
Calm3 | |
NM_007590 |
calmodulin 3 (Calm3), mRNA [NM_007590] |
KLA | .95 |
.96 |
.93 |
1.03 |
1.05 |
1.08 |
1.00 |
| ATP | .93 |
.96 |
.99 |
.97 |
.93 |
.84 |
.72 |
| KLA/ATP | .89 |
.93 |
.90 |
.91 |
1.02 |
.98 |
.70 |
|
Calm4 | |
NM_020036 |
calmodulin 4 (Calm4), mRNA [NM_020036] |
KLA | 1.02 |
.96 |
1.05 |
1.00 |
.99 |
1.00 |
1.01 |
| ATP | 1.10 |
1.05 |
1.03 |
1.01 |
.94 |
.98 |
.98 |
| KLA/ATP | .99 |
1.12 |
1.01 |
1.03 |
.98 |
1.07 |
1.02 |
|
Calm5 | |
NM_001008706 |
calmodulin 5 (Calm5), mRNA [NM_001008706] |
KLA | 1.02 |
1.11 |
.99 |
.98 |
1.07 |
1.01 |
1.09 |
| ATP | 1.07 |
1.05 |
1.04 |
1.04 |
1.01 |
1.04 |
.99 |
| KLA/ATP | 1.00 |
1.00 |
.97 |
1.07 |
1.00 |
1.07 |
.98 |
|
Calml3 | |
NM_027416 |
calmodulin-like 3 (Calml3), mRNA [NM_027416] |
KLA | 1.01 |
.95 |
1.05 |
.91 |
1.01 |
.98 |
.89 |
| ATP | .91 |
1.05 |
1.04 |
1.01 |
.93 |
1.07 |
.99 |
| KLA/ATP | 1.01 |
.96 |
.97 |
.96 |
.97 |
.92 |
.99 |
|
Camk2a | |
NM_177407 |
calcium/calmodulin-dependent protein kinase II alpha (Camk2a), transcript variant 2, mRNA [NM_177407] |
KLA | .98 |
.97 |
.98 |
.95 |
.97 |
1.02 |
.97 |
| ATP | .98 |
1.11 |
1.02 |
.89 |
.94 |
.89 |
.82 |
| KLA/ATP | .99 |
.95 |
1.02 |
.88 |
.88 |
.87 |
.87 |
|
Camk2b | |
NM_007595 |
calcium/calmodulin-dependent protein kinase II, beta (Camk2b), mRNA [NM_007595] |
KLA | 1.09 |
1.28 |
1.42 |
1.41 |
1.37 |
1.24 |
.68 |
| ATP | .94 |
.87 |
.95 |
.91 |
.67 |
.44 |
.48 |
| KLA/ATP | 1.16 |
1.24 |
1.40 |
1.13 |
1.14 |
.81 |
.49 |
|
Camk2d | |
AK032524 |
adult male olfactory brain cDNA, RIKEN full-length enriched library, clone:6430579P05 product:calcium/calmodulin-dependent protein kinase II, delta, full insert sequence. [AK032524] |
KLA | 1.31 |
1.45 |
1.42 |
1.21 |
1.34 |
1.18 |
1.16 |
| ATP | 1.04 |
1.29 |
1.39 |
1.24 |
.94 |
.91 |
1.22 |
| KLA/ATP | 1.46 |
1.64 |
1.42 |
1.24 |
1.00 |
.93 |
1.10 |
|
Camk2d | |
NM_001025439 |
calcium/calmodulin-dependent protein kinase II, delta (Camk2d), transcript variant 1, mRNA [NM_001025439] |
KLA | 1.76 |
1.75 |
1.72 |
1.89 |
1.47 |
1.55 |
1.24 |
| ATP | 1.06 |
1.06 |
.93 |
1.01 |
1.22 |
.98 |
2.28 |
| KLA/ATP | 1.84 |
1.78 |
1.40 |
1.57 |
1.07 |
.60 |
1.97 |
|
Camk2g | |
NM_178597 |
calcium/calmodulin-dependent protein kinase II gamma (Camk2g), transcript variant 1, mRNA [NM_178597] |
KLA | .23 |
.24 |
.23 |
.44 |
.70 |
.73 |
.70 |
| ATP | .91 |
.85 |
1.07 |
.86 |
.58 |
.59 |
.95 |
| KLA/ATP | .22 |
.20 |
.35 |
.25 |
.54 |
.59 |
.71 |
|
Camk4 | |
AK043457 |
7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730097A20 product:CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE IV CATALYTIC CHAIN (EC 2.7.1.123) (CAM KINASE-GR) (CAMK IV) [CONTAINS: CALSPERMIN] homolog [Mus |
KLA | .98 |
1.04 |
1.02 |
.93 |
1.03 |
1.07 |
1.07 |
| ATP | 1.01 |
.97 |
.97 |
1.10 |
1.00 |
.99 |
1.05 |
| KLA/ATP | 1.00 |
.96 |
1.02 |
.98 |
1.13 |
1.07 |
1.00 |
|
Camk4 | |
NM_009793 |
calcium/calmodulin-dependent protein kinase IV (Camk4), mRNA [NM_009793] |
KLA | .96 |
1.02 |
1.01 |
1.02 |
1.03 |
1.07 |
1.08 |
| ATP | 1.01 |
1.03 |
1.07 |
1.08 |
.99 |
1.00 |
.99 |
| KLA/ATP | 1.01 |
.95 |
.98 |
1.08 |
1.12 |
1.02 |
1.03 |
|
Cckar | |
NM_009827 |
cholecystokinin A receptor (Cckar), mRNA [NM_009827] |
KLA | 1.00 |
.97 |
1.05 |
1.07 |
.99 |
1.08 |
1.03 |
| ATP | 1.08 |
1.00 |
1.10 |
1.07 |
.94 |
1.00 |
.98 |
| KLA/ATP | .99 |
.98 |
.99 |
1.04 |
1.00 |
1.04 |
1.02 |
|
Cckbr | |
NM_007627 |
cholecystokinin B receptor (Cckbr), mRNA [NM_007627] |
KLA | 1.03 |
1.01 |
1.07 |
1.05 |
1.01 |
1.11 |
1.03 |
| ATP | .94 |
1.04 |
1.04 |
.97 |
1.01 |
1.05 |
1.02 |
| KLA/ATP | 1.03 |
.99 |
1.03 |
1.02 |
1.01 |
1.06 |
1.04 |
|
Cd38 | |
NM_007646 |
CD38 antigen (Cd38), mRNA [NM_007646] |
KLA | 3.61 |
5.39 |
8.63 |
9.62 |
24.42 |
36.25 |
76.13 |
| ATP | 1.00 |
1.05 |
1.36 |
1.70 |
2.26 |
8.41 |
7.84 |
| KLA/ATP | 4.45 |
4.89 |
5.01 |
7.93 |
5.74 |
14.08 |
40.05 |
|
Chrm1 | |
NM_001112697 |
cholinergic receptor, muscarinic 1, CNS (Chrm1), transcript variant 1, mRNA [NM_001112697] |
KLA | 1.12 |
.99 |
.97 |
1.09 |
.92 |
.91 |
.97 |
| ATP | .95 |
1.06 |
1.01 |
1.06 |
1.05 |
1.06 |
.99 |
| KLA/ATP | 1.00 |
.99 |
1.02 |
1.00 |
1.05 |
.95 |
1.01 |
|
Chrm2 | |
NM_203491 |
cholinergic receptor, muscarinic 2, cardiac (Chrm2), mRNA [NM_203491] |
KLA | 1.03 |
1.05 |
.98 |
1.02 |
1.04 |
1.06 |
1.05 |
| ATP | 1.09 |
.94 |
1.08 |
1.06 |
.98 |
1.04 |
.97 |
| KLA/ATP | 1.01 |
1.05 |
.97 |
1.01 |
.98 |
1.07 |
.99 |
|
Chrm3 | |
AK051841 |
12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230008K23 product:unclassifiable, full insert sequence. [AK051841] |
KLA | .92 |
.97 |
1.02 |
1.05 |
.96 |
.99 |
1.00 |
| ATP | 1.00 |
.99 |
.99 |
.95 |
1.05 |
1.02 |
1.01 |
| KLA/ATP | .91 |
.98 |
1.06 |
1.07 |
.94 |
1.00 |
.94 |
|
Chrm3 | |
NM_033269 |
cholinergic receptor, muscarinic 3, cardiac (Chrm3), mRNA [NM_033269] |
KLA | .91 |
.99 |
.98 |
.93 |
1.08 |
1.01 |
1.06 |
| ATP | .97 |
1.05 |
1.03 |
.95 |
.99 |
1.01 |
1.10 |
| KLA/ATP | 1.05 |
1.09 |
.99 |
1.00 |
.98 |
1.03 |
1.00 |
|
Chrm5 | |
NM_205783 |
cholinergic receptor, muscarinic 5 (Chrm5), mRNA [NM_205783] |
KLA | .98 |
1.02 |
.96 |
.98 |
1.03 |
1.02 |
1.02 |
| ATP | 1.02 |
.96 |
.96 |
1.15 |
1.00 |
1.06 |
1.04 |
| KLA/ATP | 1.02 |
.90 |
.95 |
1.05 |
1.04 |
1.05 |
.95 |
|
Chrna7 | |
NM_007390 |
cholinergic receptor, nicotinic, alpha polypeptide 7 (Chrna7), mRNA [NM_007390] |
KLA | 1.01 |
.99 |
1.04 |
.96 |
.99 |
.99 |
1.01 |
| ATP | .99 |
.97 |
1.00 |
1.00 |
.99 |
1.04 |
1.00 |
| KLA/ATP | .98 |
1.02 |
1.04 |
.99 |
.95 |
.96 |
1.07 |
|
Cysltr1 | |
NM_021476 |
cysteinyl leukotriene receptor 1 (Cysltr1), mRNA [NM_021476] |
KLA | 1.11 |
1.17 |
1.25 |
1.45 |
1.45 |
1.36 |
1.16 |
| ATP | .93 |
.87 |
1.03 |
.83 |
.42 |
.35 |
.71 |
| KLA/ATP | 1.01 |
1.03 |
1.13 |
.95 |
.59 |
.40 |
.61 |
|
Cysltr2 | |
NM_133720 |
cysteinyl leukotriene receptor 2 (Cysltr2), mRNA [NM_133720] |
KLA | 3.09 |
2.91 |
3.56 |
3.38 |
2.86 |
3.71 |
3.63 |
| ATP | 1.00 |
.91 |
1.13 |
.96 |
.77 |
1.04 |
2.02 |
| KLA/ATP | 3.07 |
3.48 |
3.37 |
2.52 |
1.66 |
1.37 |
4.59 |
|
Drd1a | |
NM_010076 |
dopamine receptor D1A (Drd1a), mRNA [NM_010076] |
KLA | .94 |
.99 |
1.02 |
.98 |
.98 |
.99 |
1.06 |
| ATP | 1.07 |
1.03 |
1.01 |
1.08 |
1.08 |
.96 |
1.04 |
| KLA/ATP | 1.04 |
1.00 |
1.01 |
1.06 |
1.08 |
1.06 |
1.09 |
|
Drd5 | |
NM_013503 |
dopamine receptor 5 (Drd5), mRNA [NM_013503] |
KLA | 1.00 |
.99 |
.99 |
.93 |
.97 |
1.04 |
1.03 |
| ATP | .99 |
1.00 |
1.00 |
1.01 |
1.01 |
1.02 |
1.00 |
| KLA/ATP | 1.05 |
.95 |
.98 |
1.00 |
.98 |
1.01 |
1.01 |
|
EG629860
| |
M17953 |
gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] |
KLA | .96 |
1.05 |
1.03 |
1.08 |
1.08 |
1.02 |
.98 |
| ATP | .97 |
.99 |
1.05 |
1.10 |
.95 |
.94 |
.91 |
| KLA/ATP | .96 |
.94 |
.97 |
1.04 |
.97 |
1.01 |
.89 |
|
Ednra | |
AK042211 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630071G03 product:SIMILAR TO ENDOTHELIN RECEPTOR TYPE A, full insert sequence. [AK042211] |
KLA | 1.00 |
1.03 |
1.03 |
.97 |
.98 |
.99 |
.99 |
| ATP | .96 |
.97 |
1.05 |
.95 |
1.05 |
1.04 |
1.02 |
| KLA/ATP | .99 |
.98 |
1.00 |
1.05 |
.97 |
.98 |
.83 |
|
Ednra | |
NM_010332 |
endothelin receptor type A (Ednra), mRNA [NM_010332] |
KLA | 1.06 |
.99 |
1.02 |
.91 |
1.05 |
1.00 |
.99 |
| ATP | 1.01 |
.98 |
1.03 |
.98 |
.98 |
1.03 |
1.06 |
| KLA/ATP | 1.01 |
1.06 |
1.04 |
.93 |
.92 |
.92 |
.97 |
|
Ednrb | |
NM_007904 |
endothelin receptor type B (Ednrb), mRNA [NM_007904] |
KLA | 3.53 |
3.62 |
3.97 |
2.91 |
1.91 |
1.83 |
.88 |
| ATP | .97 |
.95 |
1.05 |
1.80 |
4.84 |
18.19 |
9.14 |
| KLA/ATP | 3.30 |
3.37 |
3.89 |
3.06 |
2.11 |
4.82 |
10.15 |
|
Egfr | |
NM_007912 |
epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] |
KLA | 1.10 |
1.07 |
1.14 |
1.11 |
1.08 |
1.03 |
.90 |
| ATP | .99 |
1.00 |
1.04 |
.98 |
.97 |
1.15 |
1.14 |
| KLA/ATP | 1.07 |
1.10 |
1.16 |
1.08 |
1.01 |
.97 |
.94 |
|
Egfr | |
NM_207655 |
epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] |
KLA | 1.57 |
1.44 |
1.47 |
1.31 |
.96 |
.92 |
.76 |
| ATP | .97 |
.93 |
1.10 |
1.00 |
1.41 |
2.97 |
.86 |
| KLA/ATP | 1.44 |
1.50 |
1.61 |
1.30 |
1.14 |
1.21 |
.82 |
|
Erbb2 | |
NM_001003817 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2), mRNA [NM_001003817] |
KLA | 1.01 |
1.00 |
.98 |
1.01 |
.98 |
.99 |
.97 |
| ATP | .99 |
1.00 |
1.00 |
1.00 |
.96 |
.98 |
.99 |
| KLA/ATP | 1.00 |
1.01 |
1.01 |
1.02 |
.96 |
.98 |
.97 |
|
Erbb3 | |
BC049279 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian), mRNA (cDNA clone IMAGE:4460595), partial cds. [BC049279] |
KLA | .71 |
.74 |
.77 |
.92 |
1.26 |
1.39 |
1.01 |
| ATP | .92 |
.90 |
.92 |
.70 |
.43 |
.93 |
1.08 |
| KLA/ATP | .66 |
.70 |
.71 |
.61 |
.56 |
1.15 |
1.29 |
|
Erbb3 | |
NM_010153 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (Erbb3), mRNA [NM_010153] |
KLA | .98 |
.99 |
.98 |
.98 |
.98 |
1.03 |
1.01 |
| ATP | 1.01 |
1.00 |
.95 |
1.00 |
.94 |
.95 |
1.01 |
| KLA/ATP | .98 |
1.03 |
.95 |
.99 |
.99 |
.99 |
.93 |
|
Erbb4 | |
NM_010154 |
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) (Erbb4), mRNA [NM_010154] |
KLA | 1.06 |
.98 |
.93 |
.99 |
1.02 |
.98 |
.91 |
| ATP | 1.01 |
.97 |
.93 |
.96 |
1.00 |
1.01 |
1.01 |
| KLA/ATP | .94 |
.96 |
1.03 |
.99 |
.87 |
.95 |
1.02 |
|
F2r | |
NM_010169 |
coagulation factor II (thrombin) receptor (F2r), mRNA [NM_010169] |
KLA | 3.73 |
3.81 |
3.68 |
3.00 |
2.75 |
1.49 |
1.01 |
| ATP | .98 |
1.02 |
1.25 |
1.24 |
1.31 |
1.63 |
1.16 |
| KLA/ATP | 3.51 |
4.05 |
3.49 |
3.00 |
2.48 |
1.69 |
1.23 |
|
Gna11 | |
NM_010301 |
guanine nucleotide binding protein, alpha 11 (Gna11), mRNA [NM_010301] |
KLA | .62 |
.65 |
.69 |
.79 |
.94 |
1.00 |
.96 |
| ATP | 1.00 |
.94 |
.63 |
.53 |
.79 |
1.13 |
1.22 |
| KLA/ATP | .64 |
.60 |
.56 |
.55 |
.81 |
1.16 |
1.18 |
|
Gna14 | |
NM_008137 |
guanine nucleotide binding protein, alpha 14 (Gna14), mRNA [NM_008137] |
KLA | .97 |
.96 |
1.07 |
1.00 |
1.01 |
1.04 |
1.02 |
| ATP | .96 |
1.01 |
1.02 |
1.13 |
1.06 |
1.06 |
.96 |
| KLA/ATP | 1.03 |
.95 |
.93 |
1.06 |
1.13 |
1.10 |
1.05 |
|
Gna15 | |
NM_010304 |
guanine nucleotide binding protein, alpha 15 (Gna15), mRNA [NM_010304] |
KLA | 2.16 |
2.28 |
2.64 |
2.15 |
1.45 |
.98 |
.70 |
| ATP | .98 |
.89 |
.74 |
1.05 |
2.02 |
.97 |
1.07 |
| KLA/ATP | 2.18 |
2.11 |
1.63 |
1.66 |
1.69 |
1.17 |
.60 |
|
Gnal | |
NM_010307 |
guanine nucleotide binding protein, alpha stimulating, olfactory type (Gnal), transcript variant 1, mRNA [NM_010307] |
KLA | 1.01 |
.90 |
.96 |
1.20 |
1.02 |
.97 |
.95 |
| ATP | .96 |
.92 |
.97 |
1.04 |
1.35 |
1.07 |
1.05 |
| KLA/ATP | .90 |
.98 |
.97 |
1.15 |
1.26 |
1.25 |
1.36 |
|
Gnaq | |
NM_008139 |
guanine nucleotide binding protein, alpha q polypeptide (Gnaq), mRNA [NM_008139] |
KLA | .82 |
.82 |
.69 |
.64 |
.60 |
.55 |
.55 |
| ATP | 1.06 |
1.02 |
.87 |
.67 |
.50 |
.66 |
.57 |
| KLA/ATP | .82 |
.79 |
.66 |
.55 |
.41 |
.33 |
.48 |
|
Gnas | |
AF107847 |
neuroendocrine-specific Golgi protein p55 isoform 1 (XLalphas) alternatively spliced mRNA, complete cds. [AF107847] |
KLA | 1.04 |
.94 |
1.00 |
1.05 |
1.04 |
.98 |
1.00 |
| ATP | .98 |
.97 |
.96 |
1.00 |
.99 |
.98 |
1.02 |
| KLA/ATP | 1.04 |
1.02 |
.96 |
.95 |
1.01 |
.96 |
1.01 |
|
Gnas | |
AK017423 |
10 days neonate head cDNA, RIKEN full-length enriched library, clone:5530400H20 product:novel noncoding RNA overlapping the exon 1A, 1 and 2 of Gnas, full insert sequence. [AK017423] |
KLA | .85 |
1.08 |
.97 |
.92 |
1.05 |
1.03 |
1.08 |
| ATP | .99 |
1.30 |
2.11 |
1.73 |
1.23 |
1.01 |
1.02 |
| KLA/ATP | .96 |
1.06 |
1.58 |
1.34 |
1.29 |
1.05 |
.91 |
|
Gnas | |
NM_001077510 |
GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus (Gnas), transcript variant 8, mRNA [NM_001077510] |
KLA | .99 |
1.03 |
.97 |
.91 |
1.03 |
.95 |
.97 |
| ATP | 1.04 |
1.19 |
1.15 |
1.61 |
1.24 |
.91 |
1.00 |
| KLA/ATP | 1.06 |
.97 |
1.01 |
1.46 |
1.04 |
.85 |
1.01 |
|
Gnas | |
S49980 |
gb|stimulatory G protein alpha subunit {clone WC-16} [mice, whole cochlea, mRNA Partial, 356 nt]. [S49980] |
KLA | .91 |
.88 |
1.03 |
.87 |
.90 |
.84 |
1.01 |
| ATP | 1.16 |
1.22 |
1.02 |
1.55 |
1.16 |
.80 |
.99 |
| KLA/ATP | 1.01 |
1.13 |
.86 |
1.12 |
.97 |
.85 |
1.08 |
|
Grin1 | |
NM_008169 |
glutamate receptor, ionotropic, NMDA1 (zeta 1) (Grin1), mRNA [NM_008169] |
KLA | .90 |
.97 |
.91 |
.98 |
.93 |
.94 |
1.01 |
| ATP | 1.04 |
1.04 |
1.02 |
1.08 |
.96 |
.91 |
.93 |
| KLA/ATP | .90 |
.99 |
.95 |
.95 |
.94 |
.88 |
.89 |
|
Grin2a | |
NM_008170 |
glutamate receptor, ionotropic, NMDA2A (epsilon 1) (Grin2a), mRNA [NM_008170] |
KLA | 1.00 |
1.08 |
1.00 |
1.03 |
1.09 |
1.02 |
1.04 |
| ATP | .96 |
.94 |
1.00 |
.98 |
1.03 |
.97 |
1.01 |
| KLA/ATP | .95 |
1.02 |
1.03 |
.95 |
.99 |
.99 |
.95 |
|
Grin2c | |
NM_010350 |
glutamate receptor, ionotropic, NMDA2C (epsilon 3) (Grin2c), mRNA [NM_010350] |
KLA | 1.09 |
1.13 |
1.19 |
1.24 |
1.14 |
1.15 |
1.09 |
| ATP | 1.05 |
.96 |
.98 |
.98 |
.94 |
1.01 |
1.10 |
| KLA/ATP | 1.08 |
1.14 |
1.09 |
1.05 |
1.05 |
.98 |
1.01 |
|
Grin2d | |
NM_008172 |
glutamate receptor, ionotropic, NMDA2D (epsilon 4) (Grin2d), mRNA [NM_008172] |
KLA | 1.57 |
1.18 |
1.35 |
1.45 |
1.25 |
1.49 |
.91 |
| ATP | .92 |
.99 |
1.45 |
1.66 |
1.54 |
2.02 |
1.15 |
| KLA/ATP | 1.23 |
1.38 |
2.08 |
2.28 |
1.92 |
2.53 |
1.92 |
|
Grm1 | |
NM_016976 |
glutamate receptor, metabotropic 1 (Grm1), transcript variant 1, mRNA [NM_016976] |
KLA | 1.16 |
1.07 |
1.10 |
1.18 |
1.08 |
1.04 |
1.15 |
| ATP | 1.06 |
1.05 |
1.02 |
.99 |
1.00 |
1.09 |
1.02 |
| KLA/ATP | 1.04 |
1.12 |
1.06 |
1.11 |
1.10 |
1.32 |
1.35 |
|
Grm5 | |
NM_001081414 |
glutamate receptor, metabotropic 5 (Grm5), mRNA [NM_001081414] |
KLA | 1.04 |
1.05 |
1.04 |
1.04 |
1.02 |
1.01 |
1.05 |
| ATP | .99 |
1.02 |
1.03 |
1.01 |
.99 |
1.00 |
1.03 |
| KLA/ATP | 1.03 |
1.02 |
1.02 |
1.03 |
1.01 |
1.01 |
1.05 |
|
Grpr | |
NM_008177 |
gastrin releasing peptide receptor (Grpr), mRNA [NM_008177] |
KLA | 1.00 |
.96 |
.99 |
1.03 |
.99 |
1.03 |
1.04 |
| ATP | .95 |
1.00 |
1.07 |
1.00 |
1.01 |
1.03 |
1.05 |
| KLA/ATP | .96 |
1.02 |
1.06 |
1.04 |
.93 |
1.03 |
.96 |
|
Hrh1 | |
NM_008285 |
histamine receptor H1 (Hrh1), mRNA [NM_008285] |
KLA | .92 |
.94 |
.84 |
.88 |
1.27 |
1.69 |
1.61 |
| ATP | 1.05 |
.97 |
.92 |
.83 |
.85 |
.97 |
1.04 |
| KLA/ATP | .86 |
.89 |
.83 |
.74 |
.87 |
1.20 |
2.84 |
|
Hrh2 | |
NM_008286 |
histamine receptor H2 (Hrh2), transcript variant 2, mRNA [NM_008286] |
KLA | 1.18 |
1.33 |
1.70 |
1.54 |
1.69 |
1.61 |
1.52 |
| ATP | .96 |
1.10 |
.98 |
1.08 |
.99 |
1.03 |
1.35 |
| KLA/ATP | 1.25 |
1.19 |
1.15 |
1.20 |
1.09 |
1.39 |
1.92 |
|
Htr2a | |
NM_172812 |
5-hydroxytryptamine (serotonin) receptor 2A (Htr2a), mRNA [NM_172812] |
KLA | 1.00 |
1.01 |
1.03 |
1.00 |
.97 |
.96 |
.99 |
| ATP | .97 |
.97 |
.95 |
1.12 |
1.41 |
.98 |
.95 |
| KLA/ATP | .92 |
1.01 |
1.07 |
1.08 |
1.03 |
.98 |
1.06 |
|
Htr2b | |
NM_008311 |
5-hydroxytryptamine (serotonin) receptor 2B (Htr2b), mRNA [NM_008311] |
KLA | .47 |
.44 |
.41 |
.46 |
.73 |
1.91 |
1.14 |
| ATP | .90 |
.92 |
.95 |
1.02 |
1.24 |
1.47 |
11.87 |
| KLA/ATP | .44 |
.43 |
.51 |
.56 |
1.05 |
4.41 |
10.84 |
|
Htr2c | |
AK086348 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930023E13 product:5-hydroxytryptamine (serotonin) receptor 2C, full insert sequence. [AK086348] |
KLA | 1.01 |
1.01 |
1.00 |
1.03 |
1.03 |
1.04 |
1.04 |
| ATP | 1.01 |
1.00 |
1.00 |
1.04 |
1.02 |
1.03 |
.99 |
| KLA/ATP | .99 |
1.02 |
.96 |
1.07 |
1.03 |
1.06 |
1.06 |
|
Htr2c | |
NM_008312 |
5-hydroxytryptamine (serotonin) receptor 2C (Htr2c), mRNA [NM_008312] |
KLA | 1.03 |
1.08 |
1.00 |
1.05 |
1.02 |
1.02 |
.98 |
| ATP | .96 |
1.02 |
1.01 |
1.05 |
.98 |
.99 |
1.03 |
| KLA/ATP | 1.00 |
1.00 |
1.04 |
.97 |
.96 |
.96 |
.98 |
|
Htr4 | |
NM_008313 |
5 hydroxytryptamine (serotonin) receptor 4 (Htr4), mRNA [NM_008313] |
KLA | 1.02 |
1.05 |
.99 |
.99 |
1.01 |
.99 |
1.08 |
| ATP | .98 |
1.04 |
1.04 |
1.06 |
.96 |
1.02 |
1.06 |
| KLA/ATP | 1.00 |
.98 |
.97 |
1.03 |
1.02 |
1.08 |
1.00 |
|
Htr5a | |
NM_008314 |
5-hydroxytryptamine (serotonin) receptor 5A (Htr5a), mRNA [NM_008314] |
KLA | 1.08 |
1.01 |
1.14 |
1.10 |
1.13 |
1.04 |
1.08 |
| ATP | 1.09 |
.98 |
.96 |
.97 |
1.04 |
1.00 |
1.03 |
| KLA/ATP | 1.12 |
1.08 |
1.12 |
.99 |
1.00 |
1.03 |
.98 |
|
Htr5b | |
NM_010483 |
5-hydroxytryptamine (serotonin) receptor 5B (Htr5b), mRNA [NM_010483] |
KLA | .99 |
.98 |
1.01 |
.98 |
.97 |
.99 |
.98 |
| ATP | .95 |
1.00 |
1.01 |
1.01 |
1.01 |
1.06 |
.94 |
| KLA/ATP | .97 |
1.00 |
1.05 |
1.03 |
1.00 |
.93 |
1.06 |
|
Htr6 | |
NM_021358 |
5-hydroxytryptamine (serotonin) receptor 6 (Htr6), mRNA [NM_021358] |
KLA | 1.04 |
1.01 |
1.01 |
1.06 |
1.05 |
.98 |
.97 |
| ATP | 1.00 |
1.03 |
.96 |
.96 |
1.02 |
.96 |
1.02 |
| KLA/ATP | .93 |
.94 |
1.03 |
1.03 |
.91 |
1.00 |
.91 |
|
Htr7 | |
NM_008315 |
5-hydroxytryptamine (serotonin) receptor 7 (Htr7), mRNA [NM_008315] |
KLA | 1.07 |
.91 |
1.03 |
1.05 |
1.02 |
1.07 |
.97 |
| ATP | .97 |
1.02 |
1.00 |
1.03 |
1.05 |
1.05 |
.99 |
| KLA/ATP | 1.03 |
1.03 |
1.10 |
.99 |
.99 |
1.09 |
1.25 |
|
Igh-VJ55 8 | |
AY547436 |
immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] |
KLA | 1.06 |
1.05 |
1.01 |
.93 |
1.03 |
.96 |
.93 |
| ATP | .99 |
1.00 |
1.06 |
.95 |
.96 |
1.06 |
1.05 |
| KLA/ATP | .98 |
.94 |
1.07 |
.95 |
.97 |
.99 |
1.02 |
|
Igh-VJ55 8 | |
CA578712 |
gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] |
KLA | .99 |
.94 |
1.01 |
1.10 |
.93 |
.97 |
.92 |
| ATP | .93 |
1.04 |
1.01 |
.98 |
1.05 |
.96 |
.95 |
| KLA/ATP | .99 |
.95 |
.95 |
.98 |
1.02 |
.98 |
.95 |
|
Igh-VJ55 8 | |
ENSMUST00000103412 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] |
KLA | 1.01 |
.97 |
1.20 |
1.01 |
.98 |
1.44 |
1.24 |
| ATP | .99 |
.98 |
1.07 |
1.03 |
1.00 |
1.01 |
1.21 |
| KLA/ATP | .99 |
1.02 |
.96 |
1.03 |
.97 |
1.13 |
1.30 |
|
Igh-VJ55 8 | |
ENSMUST00000103413 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] |
KLA | 1.00 |
.99 |
1.06 |
1.06 |
.99 |
1.03 |
1.02 |
| ATP | 1.08 |
1.06 |
1.06 |
1.06 |
1.02 |
1.06 |
.95 |
| KLA/ATP | 1.00 |
1.04 |
1.09 |
1.02 |
1.06 |
1.02 |
.95 |
|
Igh-VJ55 8 | |
U39781 |
J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] |
KLA | .93 |
.89 |
.98 |
.97 |
1.03 |
1.00 |
.94 |
| ATP | 1.04 |
1.02 |
1.08 |
.94 |
.93 |
.90 |
.79 |
| KLA/ATP | .88 |
.89 |
.97 |
.93 |
.88 |
.92 |
.82 |
|
Itpka | |
NM_146125 |
inositol 1,4,5-trisphosphate 3-kinase A (Itpka), mRNA [NM_146125] |
KLA | 6.50 |
5.98 |
5.46 |
4.17 |
2.98 |
2.72 |
1.97 |
| ATP | 1.13 |
.98 |
1.19 |
1.19 |
2.36 |
2.47 |
1.17 |
| KLA/ATP | 7.72 |
7.92 |
10.01 |
7.02 |
8.80 |
6.84 |
1.93 |
|
Itpkc | |
AK051297 |
12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130031K05 product:weakly similar to INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE C [Homo sapiens], full insert sequence. [AK051297] |
KLA | 1.15 |
1.02 |
1.00 |
1.09 |
1.07 |
1.03 |
1.00 |
| ATP | .91 |
1.03 |
1.02 |
.99 |
.98 |
1.03 |
1.02 |
| KLA/ATP | .94 |
.95 |
1.06 |
.99 |
.95 |
.98 |
1.02 |
|
Itpkc | |
NM_181593 |
inositol 1,4,5-trisphosphate 3-kinase C (Itpkc), mRNA [NM_181593] |
KLA | .76 |
.68 |
.76 |
1.00 |
1.61 |
1.01 |
1.14 |
| ATP | 1.18 |
1.09 |
1.14 |
4.49 |
3.58 |
1.64 |
1.04 |
| KLA/ATP | .85 |
.78 |
1.05 |
2.67 |
3.12 |
1.34 |
1.41 |
|
Itpr1 | |
NM_010585 |
inositol 1,4,5-triphosphate receptor 1 (Itpr1), mRNA [NM_010585] |
KLA | 3.66 |
3.69 |
6.74 |
8.11 |
7.08 |
4.40 |
1.22 |
| ATP | 1.08 |
.95 |
1.19 |
.94 |
1.09 |
1.00 |
.68 |
| KLA/ATP | 3.48 |
3.58 |
5.86 |
6.03 |
4.01 |
2.31 |
.97 |
|
Itpr2 | |
NM_019923 |
inositol 1,4,5-triphosphate receptor 2 (Itpr2), transcript variant 1, mRNA [NM_019923] |
KLA | 1.41 |
1.38 |
1.43 |
1.42 |
1.30 |
1.07 |
1.01 |
| ATP | 1.00 |
1.00 |
.97 |
.97 |
1.07 |
1.15 |
1.06 |
| KLA/ATP | 1.39 |
1.48 |
1.64 |
1.42 |
1.07 |
.83 |
.95 |
|
Itpr3 | |
NM_080553 |
inositol 1,4,5-triphosphate receptor 3 (Itpr3), mRNA [NM_080553] |
KLA | .55 |
.51 |
.45 |
.41 |
.34 |
.34 |
.45 |
| ATP | 1.01 |
.92 |
1.02 |
.57 |
.46 |
.34 |
1.22 |
| KLA/ATP | .56 |
.48 |
.48 |
.29 |
.33 |
.27 |
.65 |
|
Lhcgr | |
NM_013582 |
luteinizing hormone/choriogonadotropin receptor (Lhcgr), mRNA [NM_013582] |
KLA | .98 |
1.06 |
.99 |
.95 |
1.01 |
1.00 |
1.04 |
| ATP | 1.01 |
.95 |
1.00 |
1.04 |
1.00 |
1.03 |
1.00 |
| KLA/ATP | 1.04 |
1.02 |
.97 |
1.01 |
1.03 |
1.04 |
.98 |
|
Ltb4r2 | |
NM_020490 |
leukotriene B4 receptor 2 (Ltb4r2), mRNA [NM_020490] |
KLA | .97 |
1.01 |
1.01 |
.99 |
1.03 |
1.04 |
1.01 |
| ATP | 1.02 |
.91 |
1.07 |
1.01 |
1.08 |
1.03 |
1.01 |
| KLA/ATP | .95 |
1.01 |
1.00 |
1.03 |
1.04 |
1.01 |
1.03 |
|
Mm.13153 0 | |
161086915 |
Unknown |
KLA | 1.00 |
1.07 |
1.14 |
1.08 |
.97 |
1.00 |
.93 |
| ATP | 1.04 |
.99 |
1.00 |
.95 |
.99 |
1.02 |
.90 |
| KLA/ATP | 1.08 |
1.18 |
1.14 |
1.16 |
1.04 |
1.06 |
1.08 |
|
Mm.1716 | |
46852154 |
Unknown |
KLA | 1.36 |
1.28 |
1.23 |
1.51 |
1.39 |
1.42 |
1.44 |
| ATP | .94 |
1.00 |
1.10 |
1.38 |
1.43 |
1.20 |
1.04 |
| KLA/ATP | 1.24 |
1.32 |
1.36 |
1.46 |
2.16 |
1.59 |
1.47 |
|
Mm.24060 7 | |
162951825 |
Unknown |
KLA | .94 |
.96 |
.91 |
1.02 |
.90 |
.84 |
.97 |
| ATP | 1.08 |
1.01 |
1.08 |
.95 |
1.04 |
.89 |
.89 |
| KLA/ATP | .93 |
1.01 |
1.05 |
.92 |
.84 |
.88 |
.76 |
|
Mm.24987 3 | |
161621251 |
Unknown |
KLA | 1.11 |
1.02 |
1.08 |
1.36 |
1.47 |
1.64 |
3.59 |
| ATP | 1.05 |
1.00 |
1.00 |
.96 |
1.04 |
1.20 |
1.13 |
| KLA/ATP | 1.08 |
1.12 |
1.23 |
1.06 |
1.09 |
1.31 |
1.81 |
|
Mm.26232 7 | |
118130063 |
Unknown |
KLA | .91 |
.88 |
.82 |
.99 |
.84 |
.98 |
.82 |
| ATP | .84 |
.72 |
.77 |
.54 |
.54 |
.50 |
.72 |
| KLA/ATP | .74 |
.71 |
.74 |
.50 |
.71 |
.60 |
.39 |
|
Mm.29073 1 | |
125347157 |
Unknown |
KLA | .98 |
.99 |
1.12 |
1.02 |
1.04 |
1.04 |
1.05 |
| ATP | 1.02 |
1.06 |
.97 |
1.05 |
.99 |
1.07 |
1.02 |
| KLA/ATP | .96 |
.96 |
.99 |
1.10 |
1.07 |
1.03 |
1.01 |
|
Mm.29105 8 | |
157057193 |
Unknown |
KLA | 1.02 |
.94 |
.97 |
.97 |
1.03 |
1.00 |
1.00 |
| ATP | 1.03 |
1.01 |
1.10 |
.95 |
.95 |
1.00 |
1.03 |
| KLA/ATP | .97 |
.93 |
1.06 |
1.02 |
1.04 |
.94 |
1.02 |
|
Mm.3159 | |
77404187 |
Unknown |
KLA | .96 |
.95 |
1.06 |
1.00 |
1.00 |
.91 |
1.05 |
| ATP | 1.06 |
.97 |
.97 |
.96 |
1.02 |
.90 |
1.05 |
| KLA/ATP | .92 |
.99 |
.96 |
.99 |
.99 |
.99 |
.98 |
|
Mm.32259 4 | |
144922605 |
Unknown |
KLA | 1.02 |
1.03 |
.98 |
.98 |
.95 |
1.00 |
1.02 |
| ATP | 1.01 |
.98 |
1.08 |
1.01 |
1.04 |
1.01 |
.97 |
| KLA/ATP | .97 |
1.08 |
1.04 |
1.02 |
1.00 |
1.01 |
1.03 |
|
Mm.33138 9 | |
158508469 |
Unknown |
KLA | .80 |
.79 |
.81 |
.82 |
.72 |
.64 |
.50 |
| ATP | .95 |
.85 |
.56 |
.48 |
.30 |
.33 |
.46 |
| KLA/ATP | .71 |
.64 |
.50 |
.41 |
.33 |
.32 |
.42 |
|
Mm.38329 7 | |
124487166 |
Unknown |
KLA | 2.05 |
2.34 |
2.70 |
2.62 |
3.57 |
3.14 |
2.09 |
| ATP | 1.14 |
1.43 |
1.16 |
2.23 |
1.65 |
1.29 |
1.61 |
| KLA/ATP | 2.51 |
2.51 |
1.90 |
3.84 |
2.23 |
2.63 |
3.57 |
|
Mm.42026
| |
84781761 |
Unknown |
KLA | .55 |
.55 |
.60 |
.65 |
.79 |
1.01 |
.87 |
| ATP | .97 |
.99 |
1.03 |
.91 |
.56 |
.43 |
.56 |
| KLA/ATP | .60 |
.58 |
.68 |
.58 |
.85 |
.96 |
1.13 |
|
Mm.44160 1 | |
145966786 |
Unknown |
KLA | 1.08 |
.94 |
1.01 |
.97 |
.79 |
.78 |
.71 |
| ATP | 1.09 |
.92 |
1.10 |
.75 |
.65 |
.92 |
.69 |
| KLA/ATP | 1.01 |
.92 |
1.16 |
.81 |
.69 |
.56 |
.63 |
|
Mm.4424 | |
110225367 |
Unknown |
KLA | .99 |
.93 |
1.01 |
1.02 |
1.00 |
.92 |
1.00 |
| ATP | .98 |
1.03 |
3.11 |
1.13 |
1.19 |
1.03 |
1.11 |
| KLA/ATP | .95 |
.97 |
.97 |
.96 |
.93 |
1.01 |
.99 |
|
Mm.44463
| |
118129851 |
Unknown |
KLA | 1.01 |
.98 |
.97 |
1.02 |
.93 |
1.06 |
1.05 |
| ATP | .97 |
1.01 |
1.04 |
1.06 |
1.02 |
1.08 |
.97 |
| KLA/ATP | 1.02 |
1.06 |
.95 |
1.04 |
1.09 |
1.14 |
1.03 |
|
Mm.54161
| |
164607143 |
Unknown |
KLA | .97 |
.99 |
1.00 |
.98 |
.95 |
.98 |
.94 |
| ATP | 1.01 |
.99 |
1.06 |
1.07 |
1.02 |
.95 |
.98 |
| KLA/ATP | .93 |
1.04 |
1.07 |
.96 |
.90 |
.95 |
.94 |
|
Mylk | |
AK044527 |
adult retina cDNA, RIKEN full-length enriched library, clone:A930019C19 product:MYOSIN LIGHT CHAIN KINASE (FRAGMENT) homolog [Mus musculus], full insert sequence. [AK044527] |
KLA | 1.10 |
.99 |
.93 |
1.01 |
1.00 |
1.07 |
1.01 |
| ATP | 1.02 |
.97 |
.92 |
.99 |
1.02 |
.97 |
1.06 |
| KLA/ATP | 1.01 |
1.03 |
1.05 |
.97 |
.91 |
1.00 |
.96 |
|
Mylk | |
NM_139300 |
myosin, light polypeptide kinase (Mylk), mRNA [NM_139300] |
KLA | 1.05 |
1.15 |
1.22 |
1.24 |
1.33 |
1.21 |
.50 |
| ATP | 1.05 |
1.08 |
.96 |
.91 |
.79 |
.71 |
.40 |
| KLA/ATP | 1.14 |
1.18 |
1.15 |
1.04 |
.90 |
.79 |
.48 |
|
Mylk2 | |
NM_001081044 |
myosin, light polypeptide kinase 2, skeletal muscle (Mylk2), mRNA [NM_001081044] |
KLA | 1.17 |
1.21 |
1.11 |
1.25 |
1.17 |
1.10 |
1.06 |
| ATP | .94 |
1.05 |
1.06 |
1.10 |
1.33 |
1.33 |
1.27 |
| KLA/ATP | 1.15 |
1.25 |
1.14 |
1.21 |
1.32 |
1.29 |
1.45 |
|
Mylk3 | |
AK052858 |
16 days neonate heart cDNA, RIKEN full-length enriched library, clone:D830007F02 product:Weakly similar to myosin light chain kinase, full insert sequence. [AK052858] |
KLA | 1.06 |
1.02 |
.95 |
.98 |
1.01 |
1.04 |
1.02 |
| ATP | 1.02 |
1.06 |
1.00 |
1.01 |
.97 |
1.01 |
.98 |
| KLA/ATP | 1.08 |
1.00 |
.94 |
1.13 |
1.07 |
1.08 |
1.05 |
|
Nos1 | |
NM_008712 |
nitric oxide synthase 1, neuronal (Nos1), mRNA [NM_008712] |
KLA | 1.01 |
1.01 |
1.02 |
.99 |
1.02 |
1.02 |
1.01 |
| ATP | 1.01 |
1.03 |
1.02 |
1.04 |
1.03 |
1.01 |
1.00 |
| KLA/ATP | 1.05 |
1.02 |
1.02 |
1.00 |
1.02 |
1.03 |
1.03 |
|
Nos2 | |
NM_010927 |
nitric oxide synthase 2, inducible, macrophage (Nos2), mRNA [NM_010927] |
KLA | 13.50 |
16.36 |
25.65 |
23.25 |
24.78 |
15.99 |
6.48 |
| ATP | 1.03 |
1.03 |
1.48 |
1.66 |
1.65 |
5.55 |
1.70 |
| KLA/ATP | 16.01 |
17.41 |
19.06 |
25.50 |
20.84 |
29.92 |
29.80 |
|
Nos3 | |
NM_008713 |
nitric oxide synthase 3, endothelial cell (Nos3), mRNA [NM_008713] |
KLA | .83 |
.79 |
.76 |
.78 |
.77 |
.85 |
.96 |
| ATP | 1.03 |
1.09 |
1.03 |
1.02 |
.85 |
.96 |
1.84 |
| KLA/ATP | .80 |
.78 |
.79 |
.80 |
.79 |
.78 |
.91 |
|
Ntsr1 | |
NM_018766 |
neurotensin receptor 1 (Ntsr1), mRNA [NM_018766] |
KLA | 1.04 |
.98 |
.97 |
1.04 |
1.01 |
.98 |
.99 |
| ATP | .96 |
.99 |
.98 |
1.00 |
.94 |
.99 |
1.04 |
| KLA/ATP | .95 |
.95 |
1.06 |
.99 |
1.00 |
.93 |
.95 |
|
Orai1 | |
NM_175423 |
ORAI calcium release-activated calcium modulator 1 (Orai1), mRNA [NM_175423] |
KLA | .54 |
.57 |
.51 |
.71 |
1.13 |
1.52 |
1.43 |
| ATP | 1.00 |
1.03 |
1.00 |
1.24 |
.85 |
1.56 |
1.87 |
| KLA/ATP | .56 |
.50 |
.50 |
.71 |
.77 |
1.26 |
2.53 |
|
Orai2 | |
NM_178751 |
ORAI calcium release-activated calcium modulator 2 (Orai2), mRNA [NM_178751] |
KLA | 1.98 |
1.83 |
1.57 |
1.82 |
2.65 |
2.79 |
2.26 |
| ATP | .96 |
1.05 |
1.23 |
2.54 |
2.76 |
2.36 |
1.18 |
| KLA/ATP | 1.87 |
1.93 |
1.64 |
2.15 |
1.81 |
1.83 |
2.51 |
|
Orai3 | |
NM_198424 |
ORAI calcium release-activated calcium modulator 3 (Orai3), mRNA [NM_198424] |
KLA | .68 |
.68 |
.77 |
.74 |
.92 |
.88 |
.93 |
| ATP | 1.10 |
1.10 |
.90 |
.79 |
.36 |
.35 |
.74 |
| KLA/ATP | .73 |
.73 |
.65 |
.60 |
.40 |
.32 |
.82 |
|
Oxtr | |
D86599 |
gb|Mus sp. mRNA for oxytocin receptor, complete cds. [D86599] |
KLA | 1.06 |
.99 |
1.04 |
1.10 |
1.01 |
.98 |
1.02 |
| ATP | 1.07 |
1.04 |
1.06 |
.96 |
1.02 |
1.01 |
1.00 |
| KLA/ATP | 1.01 |
1.00 |
.79 |
1.04 |
1.02 |
.99 |
1.01 |
|
Oxtr | |
NM_001081147 |
oxytocin receptor (Oxtr), mRNA [NM_001081147] |
KLA | 1.00 |
1.00 |
.99 |
.95 |
.99 |
1.00 |
.99 |
| ATP | 1.06 |
.99 |
1.00 |
1.01 |
.96 |
.97 |
1.03 |
| KLA/ATP | .94 |
1.08 |
1.00 |
1.00 |
.94 |
.94 |
.98 |
|
P2rx1 | |
NM_008771 |
purinergic receptor P2X, ligand-gated ion channel, 1 (P2rx1), mRNA [NM_008771] |
KLA | .98 |
1.02 |
1.06 |
1.04 |
1.03 |
.94 |
.97 |
| ATP | 1.00 |
.97 |
1.01 |
.95 |
.99 |
1.05 |
1.03 |
| KLA/ATP | 1.08 |
1.00 |
1.03 |
.98 |
.92 |
1.01 |
1.09 |
|
P2rx2 | |
NM_153400 |
purinergic receptor P2X, ligand-gated ion channel, 2 (P2rx2), mRNA [NM_153400] |
KLA | 1.15 |
1.07 |
1.12 |
1.19 |
1.18 |
1.20 |
.99 |
| ATP | .97 |
1.09 |
1.30 |
1.43 |
1.29 |
1.17 |
1.07 |
| KLA/ATP | 1.15 |
1.13 |
1.45 |
1.53 |
1.38 |
1.31 |
1.22 |
|
P2rx3 | |
AK053021 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930017N16 product:hypothetical protein, full insert sequence. [AK053021] |
KLA | .97 |
.96 |
1.03 |
1.04 |
1.02 |
1.00 |
1.05 |
| ATP | 1.00 |
1.02 |
1.00 |
1.03 |
1.01 |
.96 |
1.02 |
| KLA/ATP | .96 |
1.04 |
.96 |
.91 |
.98 |
1.04 |
1.02 |
|
P2rx3 | |
NM_145526 |
purinergic receptor P2X, ligand-gated ion channel, 3 (P2rx3), mRNA [NM_145526] |
KLA | .86 |
1.01 |
1.09 |
1.01 |
.99 |
1.10 |
1.14 |
| ATP | 1.03 |
.96 |
1.12 |
1.14 |
.96 |
1.03 |
.99 |
| KLA/ATP | .98 |
.99 |
1.09 |
1.10 |
1.04 |
1.06 |
1.00 |
|
P2rx4 | |
NM_011026 |
purinergic receptor P2X, ligand-gated ion channel 4 (P2rx4), mRNA [NM_011026] |
KLA | 1.43 |
1.51 |
1.72 |
1.88 |
2.11 |
2.56 |
3.11 |
| ATP | 1.00 |
.99 |
.85 |
.91 |
.93 |
1.13 |
1.98 |
| KLA/ATP | 1.50 |
1.53 |
1.43 |
1.30 |
1.22 |
1.81 |
3.72 |
|
P2rx5 | |
NM_033321 |
purinergic receptor P2X, ligand-gated ion channel, 5 (P2rx5), mRNA [NM_033321] |
KLA | 1.05 |
1.08 |
1.06 |
1.03 |
.99 |
.97 |
.99 |
| ATP | .92 |
.96 |
.94 |
.97 |
1.02 |
1.72 |
3.00 |
| KLA/ATP | 1.11 |
1.04 |
.98 |
.96 |
.98 |
1.39 |
2.14 |
|
P2rx6 | |
AK054195 |
2 days pregnant adult female oviduct cDNA, RIKEN full-length enriched library, clone:E230027A21 product:purinergic receptor P2X-like 1, orphan receptor, full insert sequence. [AK054195] |
KLA | .98 |
.97 |
1.02 |
1.01 |
1.03 |
1.01 |
.98 |
| ATP | 1.02 |
1.06 |
1.03 |
.95 |
1.05 |
.99 |
1.01 |
| KLA/ATP | .98 |
1.03 |
1.03 |
1.05 |
1.01 |
1.06 |
1.06 |
|
P2rx6 | |
NM_011028 |
purinergic receptor P2X, ligand-gated ion channel, 6 (P2rx6), mRNA [NM_011028] |
KLA | .91 |
.93 |
.99 |
1.00 |
.94 |
.87 |
.93 |
| ATP | .98 |
.97 |
1.05 |
.95 |
.96 |
.91 |
.93 |
| KLA/ATP | 1.03 |
.92 |
.99 |
.88 |
.89 |
.90 |
.88 |
|
P2rx7 | |
NM_011027 |
purinergic receptor P2X, ligand-gated ion channel, 7 (P2rx7), transcript variant 1, mRNA [NM_011027] |
KLA | .52 |
.52 |
.50 |
.59 |
.67 |
.98 |
.80 |
| ATP | .93 |
.87 |
1.11 |
.79 |
.57 |
.48 |
.52 |
| KLA/ATP | .50 |
.50 |
.63 |
.48 |
.87 |
.97 |
1.03 |
|
Pde1a | |
NM_001009978 |
phosphodiesterase 1A, calmodulin-dependent (Pde1a), transcript variant 7, mRNA [NM_001009978] |
KLA | 1.42 |
1.46 |
1.58 |
1.35 |
1.43 |
1.21 |
1.25 |
| ATP | 1.02 |
1.01 |
1.07 |
1.13 |
1.50 |
1.46 |
1.08 |
| KLA/ATP | 1.44 |
1.52 |
1.27 |
1.38 |
1.23 |
1.40 |
1.41 |
|
Pde1a | |
NM_016744 |
phosphodiesterase 1A, calmodulin-dependent (Pde1a), mRNA [NM_016744] |
KLA | .98 |
.99 |
1.03 |
1.04 |
1.02 |
.96 |
1.04 |
| ATP | 1.02 |
1.02 |
1.05 |
1.03 |
1.00 |
.98 |
.98 |
| KLA/ATP | .99 |
1.00 |
1.08 |
1.03 |
1.01 |
1.04 |
1.00 |
|
Pde1b | |
NM_008800 |
phosphodiesterase 1B, Ca2+-calmodulin dependent (Pde1b), mRNA [NM_008800] |
KLA | 1.53 |
1.78 |
1.80 |
1.94 |
2.87 |
2.77 |
1.81 |
| ATP | 1.16 |
1.04 |
.98 |
1.15 |
1.27 |
1.30 |
.81 |
| KLA/ATP | 1.71 |
1.80 |
1.46 |
1.38 |
1.25 |
1.92 |
2.12 |
|
Pde1c | |
ENSMUST00000114327 |
ens|Calcium/calmodulin-dependent 3,5-cyclic nucleotide phosphodiesterase 1C (EC 3.1.4.17) (Cam-PDE 1C). [Source:Uniprot/SWISSPROT;Acc:Q64338] [ENSMUST00000114327] |
KLA | .94 |
1.03 |
1.01 |
.96 |
1.09 |
1.05 |
1.04 |
| ATP | 1.06 |
1.04 |
1.02 |
1.04 |
1.02 |
1.03 |
.96 |
| KLA/ATP | .93 |
.96 |
.99 |
1.11 |
1.04 |
1.08 |
1.01 |
|
Pde1c | |
NM_001025568 |
phosphodiesterase 1C (Pde1c), transcript variant 2, mRNA [NM_001025568] |
KLA | .90 |
.87 |
.88 |
.83 |
.73 |
.72 |
.74 |
| ATP | .93 |
1.03 |
1.06 |
.92 |
.88 |
.78 |
.74 |
| KLA/ATP | .96 |
.94 |
.95 |
.91 |
.84 |
.72 |
.72 |
|
Pde1c | |
NM_011054 |
phosphodiesterase 1C (Pde1c), transcript variant 1, mRNA [NM_011054] |
KLA | .96 |
.98 |
.90 |
.96 |
.91 |
1.01 |
.93 |
| ATP | .93 |
.95 |
.99 |
.94 |
.94 |
.92 |
.95 |
| KLA/ATP | 1.00 |
.91 |
.81 |
1.05 |
1.01 |
.88 |
.88 |
|
Pdgfra | |
NM_011058 |
platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA [NM_011058] |
KLA | 1.02 |
1.05 |
1.02 |
1.01 |
1.03 |
1.03 |
1.01 |
| ATP | 1.01 |
1.02 |
1.03 |
1.04 |
1.00 |
1.01 |
1.01 |
| KLA/ATP | 1.01 |
1.01 |
.99 |
1.03 |
1.02 |
1.03 |
1.01 |
|
Pdgfrb | |
NM_008809 |
platelet derived growth factor receptor, beta polypeptide (Pdgfrb), mRNA [NM_008809] |
KLA | 4.85 |
5.49 |
4.56 |
3.94 |
3.71 |
2.05 |
1.51 |
| ATP | .99 |
1.00 |
1.11 |
1.27 |
1.02 |
1.83 |
1.23 |
| KLA/ATP | 5.09 |
5.86 |
4.30 |
2.51 |
1.74 |
1.84 |
3.23 |
|
Phka1 | |
NM_008832 |
phosphorylase kinase alpha 1 (Phka1), transcript variant 1, mRNA [NM_008832] |
KLA | .89 |
.77 |
.77 |
.83 |
.74 |
.79 |
.89 |
| ATP | 1.10 |
1.03 |
.90 |
.88 |
.69 |
.72 |
.79 |
| KLA/ATP | .83 |
.78 |
.80 |
.70 |
.67 |
.76 |
.66 |
|
Phka2 | |
AK045618 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230216B06 product:PHOSPHORYLASE B KINASE ALPHA REGULATORY CHAIN, LIVER ISOFORM (PHOSPHORYLASE KINASE ALPHA L SUBUNIT)homolog [Homo sapiens], full insert sequ |
KLA | .48 |
.47 |
.52 |
.56 |
.57 |
.60 |
.48 |
| ATP | .79 |
.70 |
.60 |
.56 |
.50 |
.49 |
.58 |
| KLA/ATP | .45 |
.46 |
.53 |
.55 |
.58 |
.48 |
.47 |
|
Phka2 | |
NM_172783 |
phosphorylase kinase alpha 2 (Phka2), mRNA [NM_172783] |
KLA | .66 |
.67 |
.61 |
.52 |
.46 |
.48 |
.52 |
| ATP | 1.06 |
1.17 |
.74 |
.86 |
.45 |
.32 |
.60 |
| KLA/ATP | .76 |
.68 |
.42 |
.51 |
.31 |
.31 |
.50 |
|
Phkb | |
AK089493 |
B6-derived CD11 +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F730039M10 product:similar to phosphorylase kinase (EC 2.7.1.38) beta chain [Homo sapiens], full insert sequence. [AK089493] |
KLA | .90 |
.83 |
.71 |
.84 |
1.04 |
.89 |
.91 |
| ATP | .96 |
1.05 |
.83 |
.72 |
.77 |
.76 |
.85 |
| KLA/ATP | .87 |
.87 |
.76 |
.71 |
.78 |
.71 |
.77 |
|
Phkb | |
NM_199446 |
phosphorylase kinase beta (Phkb), mRNA [NM_199446] |
KLA | .94 |
.94 |
.95 |
.93 |
.83 |
.77 |
.79 |
| ATP | .96 |
1.02 |
.94 |
.86 |
.51 |
.38 |
.60 |
| KLA/ATP | .91 |
.93 |
.76 |
.71 |
.45 |
.38 |
.44 |
|
Phkg1 | |
NM_011079 |
phosphorylase kinase gamma 1 (Phkg1), mRNA [NM_011079] |
KLA | 1.00 |
.98 |
1.06 |
1.06 |
.95 |
.99 |
.94 |
| ATP | 1.02 |
.98 |
.91 |
.99 |
1.00 |
.91 |
.96 |
| KLA/ATP | 1.02 |
1.11 |
1.01 |
.99 |
1.00 |
.92 |
1.09 |
|
Phkg2 | |
AK089062 |
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430038C01 product:5phosphorylase kinase, gamma 2 (testis), full insert sequence [AK089062] |
KLA | .93 |
.90 |
.88 |
.86 |
.99 |
.79 |
.89 |
| ATP | 1.10 |
1.05 |
.68 |
.73 |
1.05 |
.92 |
.98 |
| KLA/ATP | .87 |
.84 |
.69 |
.79 |
.93 |
.97 |
1.10 |
|
Phkg2 | |
NM_026888 |
phosphorylase kinase, gamma 2 (testis) (Phkg2), mRNA [NM_026888] |
KLA | .88 |
.86 |
.98 |
.96 |
1.13 |
1.02 |
.92 |
| ATP | 1.19 |
1.12 |
1.02 |
1.23 |
1.17 |
1.23 |
1.22 |
| KLA/ATP | 1.04 |
1.06 |
1.00 |
1.13 |
1.25 |
1.33 |
1.64 |
|
Plcb1 | |
AK129166 |
mRNA for mKIAA0581 protein [AK129166] |
KLA | 1.02 |
.98 |
.91 |
.91 |
.92 |
.95 |
.89 |
| ATP | 1.03 |
1.02 |
1.02 |
1.01 |
.90 |
1.02 |
1.04 |
| KLA/ATP | .98 |
.97 |
.91 |
.93 |
.92 |
1.01 |
1.16 |
|
Plcb1 | |
NM_019677 |
phospholipase C, beta 1 (Plcb1), mRNA [NM_019677] |
KLA | .99 |
.94 |
.95 |
.97 |
.93 |
.92 |
.91 |
| ATP | 1.00 |
.96 |
.99 |
.95 |
.99 |
1.03 |
.98 |
| KLA/ATP | .93 |
.96 |
.94 |
.93 |
.87 |
1.00 |
1.06 |
|
Plcb2 | |
NM_177568 |
phospholipase C, beta 2 (Plcb2), mRNA [NM_177568] |
KLA | .70 |
.68 |
.64 |
.67 |
.65 |
.76 |
.88 |
| ATP | .95 |
.94 |
1.04 |
.94 |
.72 |
.57 |
1.19 |
| KLA/ATP | .69 |
.68 |
.72 |
.63 |
.65 |
.55 |
.70 |
|
Plcb3 | |
NM_008874 |
phospholipase C, beta 3 (Plcb3), mRNA [NM_008874] |
KLA | 1.72 |
1.78 |
1.82 |
1.65 |
1.67 |
1.44 |
1.21 |
| ATP | .97 |
1.04 |
.81 |
.87 |
.78 |
.88 |
.94 |
| KLA/ATP | 1.69 |
1.89 |
1.44 |
1.66 |
1.12 |
.73 |
.93 |
|
Plcb4 | |
AK082509 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230058B11 product:unclassifiable, full insert sequence. [AK082509] |
KLA | 1.06 |
1.03 |
.97 |
.98 |
1.02 |
1.01 |
.99 |
| ATP | .99 |
1.07 |
1.09 |
.95 |
.97 |
.97 |
1.02 |
| KLA/ATP | .98 |
1.00 |
1.03 |
.96 |
1.02 |
.91 |
.98 |
|
Plcb4 | |
NM_013829 |
phospholipase C, beta 4 (Plcb4), mRNA [NM_013829] |
KLA | .88 |
.94 |
.81 |
.82 |
.81 |
.86 |
1.01 |
| ATP | 1.00 |
1.01 |
.92 |
.93 |
.88 |
.85 |
.89 |
| KLA/ATP | .97 |
.94 |
.78 |
.80 |
.78 |
.86 |
.97 |
|
Plcd1 | |
NM_019676 |
phospholipase C, delta 1 (Plcd1), mRNA [NM_019676] |
KLA | 2.80 |
2.76 |
2.50 |
2.05 |
1.09 |
.66 |
1.49 |
| ATP | .93 |
.94 |
1.22 |
1.10 |
.99 |
1.35 |
.50 |
| KLA/ATP | 2.55 |
2.84 |
3.38 |
2.74 |
1.98 |
1.32 |
.80 |
|
Plcd3 | |
NM_152813 |
phospholipase C, delta 3 (Plcd3), mRNA [NM_152813] |
KLA | .58 |
.56 |
.49 |
.61 |
.70 |
.74 |
.87 |
| ATP | .98 |
1.07 |
.91 |
.92 |
.80 |
.96 |
1.23 |
| KLA/ATP | .58 |
.55 |
.59 |
.61 |
.75 |
1.03 |
1.68 |
|
Plcd4 | |
NM_148937 |
phospholipase C, delta 4 (Plcd4), transcript variant 2, mRNA [NM_148937] |
KLA | 1.04 |
.99 |
1.00 |
.99 |
.95 |
1.02 |
1.06 |
| ATP | .99 |
.98 |
.99 |
1.13 |
1.00 |
1.02 |
1.04 |
| KLA/ATP | 1.04 |
1.01 |
1.00 |
.97 |
1.10 |
.99 |
1.02 |
|
Plce1 | |
AK035546 |
adult male urinary bladder cDNA, RIKEN full-length enriched library, clone:9530064F18 product:PANCREAS-ENRICHED PHOSPHOLIPASE C homolog [Homo sapiens], full insert sequence. [AK035546] |
KLA | .99 |
1.08 |
1.03 |
1.00 |
1.06 |
1.04 |
.97 |
| ATP | 1.04 |
1.01 |
1.02 |
1.01 |
.96 |
1.01 |
1.06 |
| KLA/ATP | .98 |
.98 |
.93 |
1.02 |
.95 |
.93 |
.97 |
|
Plce1 | |
BC025027 |
phospholipase C, epsilon 1, mRNA (cDNA clone IMAGE:4948638), with apparent retained intron. [BC025027] |
KLA | 1.07 |
1.12 |
1.04 |
1.10 |
1.07 |
1.04 |
1.04 |
| ATP | 1.00 |
.96 |
1.06 |
.99 |
.98 |
.96 |
1.01 |
| KLA/ATP | 1.21 |
1.06 |
1.13 |
1.09 |
1.00 |
1.08 |
1.14 |
|
Plce1 | |
NM_019588 |
phospholipase C, epsilon 1 (Plce1), mRNA [NM_019588] |
KLA | .98 |
1.03 |
.99 |
.96 |
1.01 |
1.04 |
.96 |
| ATP | .98 |
.99 |
1.02 |
1.13 |
.99 |
1.01 |
1.00 |
| KLA/ATP | .97 |
1.11 |
1.00 |
1.07 |
.93 |
1.06 |
.99 |
|
Plcg2 | |
NM_172285 |
phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] |
KLA | .76 |
.74 |
.68 |
.66 |
.71 |
.92 |
.95 |
| ATP | .96 |
.90 |
.95 |
.87 |
.81 |
.79 |
.91 |
| KLA/ATP | .76 |
.71 |
.69 |
.62 |
.72 |
.78 |
.68 |
|
Plcz1 | |
NM_054066 |
phospholipase C, zeta 1 (Plcz1), mRNA [NM_054066] |
KLA | 1.02 |
.99 |
.97 |
1.04 |
.98 |
.95 |
.98 |
| ATP | 1.01 |
1.03 |
1.03 |
.98 |
.97 |
1.00 |
1.04 |
| KLA/ATP | 1.02 |
1.04 |
1.03 |
.99 |
1.01 |
1.00 |
1.01 |
|
Pln | |
NM_023129 |
phospholamban (Pln), mRNA [NM_023129] |
KLA | 1.01 |
1.03 |
1.07 |
1.02 |
1.01 |
1.01 |
.97 |
| ATP | 1.02 |
1.00 |
.91 |
1.00 |
.98 |
.99 |
.98 |
| KLA/ATP | 1.01 |
1.07 |
1.08 |
.93 |
.99 |
1.01 |
.95 |
|
Ppif | |
NM_134084 |
peptidylprolyl isomerase F (cyclophilin F) (Ppif), nuclear gene encoding mitochondrial protein, mRNA [NM_134084] |
KLA | 1.06 |
1.10 |
1.37 |
1.26 |
1.55 |
1.32 |
1.54 |
| ATP | 1.08 |
1.07 |
1.15 |
2.39 |
1.83 |
1.20 |
1.17 |
| KLA/ATP | 1.17 |
1.17 |
1.33 |
2.50 |
2.70 |
1.72 |
1.06 |
|
Ppp3ca | |
NM_008913 |
protein phosphatase 3, catalytic subunit, alpha isoform (Ppp3ca), mRNA [NM_008913] |
KLA | .76 |
.85 |
.81 |
.85 |
.73 |
.70 |
.52 |
| ATP | .96 |
.78 |
.55 |
.46 |
.31 |
.33 |
.48 |
| KLA/ATP | .74 |
.64 |
.52 |
.42 |
.37 |
.36 |
.45 |
|
Ppp3cb | |
AK135203 |
12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720421K10 product:protein phosphatase 3, catalytic subunit, beta isoform, full insert sequence. [AK135203] |
KLA | 1.74 |
1.57 |
1.91 |
1.59 |
1.47 |
1.26 |
1.40 |
| ATP | 1.17 |
1.03 |
1.30 |
1.00 |
.81 |
.62 |
1.37 |
| KLA/ATP | 1.68 |
1.70 |
1.91 |
1.37 |
1.09 |
.47 |
1.13 |
|
Ppp3cb | |
AK171904 |
activated spleen cDNA, RIKEN full-length enriched library, clone:F830018L06 product:Protein phosphatase 3 catalytic subunit beta3 (EC 3.1.3.16) (Serine [AK171904] |
KLA | 1.29 |
1.29 |
1.21 |
1.15 |
1.22 |
1.13 |
1.28 |
| ATP | .90 |
.86 |
.80 |
.98 |
.94 |
.73 |
.92 |
| KLA/ATP | 1.06 |
1.03 |
.77 |
1.04 |
.92 |
.68 |
.90 |
|
Ppp3cb | |
NM_008914 |
protein phosphatase 3, catalytic subunit, beta isoform (Ppp3cb), mRNA [NM_008914] |
KLA | 1.21 |
1.29 |
1.38 |
1.24 |
1.29 |
1.08 |
1.23 |
| ATP | 1.15 |
1.31 |
1.09 |
1.29 |
.86 |
.60 |
.64 |
| KLA/ATP | 1.33 |
1.40 |
1.04 |
1.28 |
.79 |
.58 |
.73 |
|
Ppp3cc | |
AK037563 |
16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026K22 product:unclassifiable, full insert sequence [AK037563] |
KLA | 1.27 |
1.18 |
1.21 |
1.15 |
1.01 |
.92 |
1.36 |
| ATP | .96 |
1.09 |
1.10 |
1.03 |
.85 |
1.06 |
1.47 |
| KLA/ATP | 1.17 |
1.24 |
1.07 |
1.13 |
.91 |
.88 |
1.36 |
|
Ppp3cc | |
NM_008915 |
protein phosphatase 3, catalytic subunit, gamma isoform (Ppp3cc), mRNA [NM_008915] |
KLA | 1.64 |
1.81 |
1.79 |
1.35 |
.90 |
.70 |
1.31 |
| ATP | .90 |
.90 |
1.13 |
.93 |
.86 |
1.40 |
1.60 |
| KLA/ATP | 1.45 |
1.62 |
1.74 |
1.47 |
1.04 |
1.01 |
1.31 |
|
Ppp3r1 | |
NM_024459 |
protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) (Ppp3r1), mRNA [NM_024459] |
KLA | 1.02 |
1.17 |
.93 |
1.27 |
1.15 |
1.30 |
1.30 |
| ATP | .97 |
.95 |
.77 |
.91 |
.99 |
1.18 |
1.10 |
| KLA/ATP | 1.12 |
1.04 |
.88 |
1.00 |
1.10 |
1.10 |
1.07 |
|
Ppp3r2 | |
NM_001004025 |
protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) (Ppp3r2), mRNA [NM_001004025] |
KLA | 1.03 |
1.05 |
1.06 |
1.08 |
1.12 |
1.05 |
1.04 |
| ATP | 1.00 |
1.02 |
1.04 |
1.04 |
.99 |
.99 |
1.01 |
| KLA/ATP | 1.04 |
1.12 |
1.03 |
1.09 |
1.00 |
.99 |
1.00 |
|
Prkaca | |
NM_008854 |
protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] |
KLA | .71 |
.74 |
.72 |
.70 |
.72 |
.84 |
.85 |
| ATP | 1.05 |
.98 |
.89 |
.92 |
.76 |
.60 |
1.02 |
| KLA/ATP | .79 |
.74 |
.55 |
.65 |
.60 |
.65 |
.93 |
|
Prkacb | |
NM_011100 |
protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] |
KLA | .69 |
.70 |
.66 |
.58 |
.51 |
.55 |
.59 |
| ATP | 1.02 |
1.19 |
.97 |
1.01 |
.69 |
.38 |
.56 |
| KLA/ATP | .72 |
.73 |
.57 |
.62 |
.47 |
.41 |
.45 |
|
Prkca | |
NM_011101 |
protein kinase C, alpha (Prkca), mRNA [NM_011101] |
KLA | 1.00 |
.96 |
.94 |
.95 |
.95 |
.89 |
.96 |
| ATP | 1.00 |
1.03 |
.91 |
.94 |
.82 |
.87 |
1.13 |
| KLA/ATP | 1.02 |
.95 |
.91 |
.86 |
.78 |
.84 |
.94 |
|
Prkcb1 | |
NM_008855 |
protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] |
KLA | .92 |
.95 |
.93 |
.78 |
.77 |
1.08 |
1.83 |
| ATP | 1.03 |
1.12 |
1.09 |
1.23 |
.90 |
2.08 |
.96 |
| KLA/ATP | .98 |
.99 |
.82 |
.89 |
.62 |
1.01 |
1.08 |
|
Prkcc | |
NM_011102 |
protein kinase C, gamma (Prkcc), mRNA [NM_011102] |
KLA | 1.02 |
1.04 |
1.11 |
1.04 |
.96 |
1.02 |
1.05 |
| ATP | .98 |
.98 |
1.05 |
1.03 |
1.08 |
.96 |
.95 |
| KLA/ATP | 1.21 |
1.16 |
1.09 |
1.07 |
1.04 |
.98 |
.93 |
|
Prkx | |
NM_016979 |
protein kinase, X-linked (Prkx), mRNA [NM_016979] |
KLA | 3.61 |
3.79 |
4.67 |
4.66 |
4.85 |
4.19 |
1.43 |
| ATP | .98 |
.90 |
.63 |
.61 |
1.12 |
1.90 |
1.29 |
| KLA/ATP | 3.56 |
3.36 |
2.62 |
2.06 |
2.26 |
2.87 |
2.31 |
|
Ptafr | |
AF004858 |
platelet activating factor receptor mRNA, partial cds. [AF004858] |
KLA | 1.20 |
1.24 |
1.22 |
1.15 |
1.15 |
1.23 |
1.40 |
| ATP | 1.03 |
1.05 |
1.04 |
1.19 |
1.37 |
1.33 |
1.63 |
| KLA/ATP | 1.28 |
1.33 |
1.17 |
1.25 |
1.29 |
1.50 |
1.90 |
|
Ptafr | |
NM_001081211 |
platelet-activating factor receptor (Ptafr), mRNA [NM_001081211] |
KLA | 1.73 |
1.73 |
1.60 |
1.31 |
1.61 |
1.84 |
2.08 |
| ATP | 1.06 |
1.10 |
.98 |
1.24 |
2.12 |
2.22 |
3.21 |
| KLA/ATP | 1.93 |
1.99 |
1.47 |
1.65 |
1.83 |
2.58 |
5.06 |
|
Ptger3 | |
D17406 |
mRNA for prostaglandin E receptor EP3 subtype, complete cds [D17406] |
KLA | 1.04 |
.92 |
1.04 |
1.06 |
.98 |
.97 |
1.07 |
| ATP | .97 |
.96 |
1.06 |
.97 |
.99 |
.98 |
1.07 |
| KLA/ATP | 1.00 |
1.02 |
.98 |
1.00 |
1.01 |
1.05 |
.95 |
|
Ptger3 | |
NM_011196 |
prostaglandin E receptor 3 (subtype EP3) (Ptger3), mRNA [NM_011196] |
KLA | 1.06 |
1.00 |
1.01 |
.99 |
.97 |
.98 |
.93 |
| ATP | 1.00 |
.98 |
.94 |
.99 |
1.09 |
1.10 |
.97 |
| KLA/ATP | 1.01 |
1.02 |
.92 |
.96 |
1.07 |
1.30 |
1.08 |
|
Ptgfr | |
AK086563 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930037F10 product:unclassifiable, full insert sequence [AK086563] |
KLA | 1.02 |
.98 |
1.02 |
.98 |
.99 |
.95 |
1.01 |
| ATP | .94 |
1.02 |
1.02 |
.96 |
1.04 |
1.00 |
.90 |
| KLA/ATP | 1.02 |
1.07 |
.99 |
.87 |
1.00 |
1.02 |
.96 |
|
Ptgfr | |
NM_008966 |
prostaglandin F receptor (Ptgfr), mRNA [NM_008966] |
KLA | 1.07 |
.96 |
.99 |
.99 |
.97 |
.97 |
.98 |
| ATP | .94 |
1.03 |
.98 |
1.00 |
1.03 |
1.05 |
1.10 |
| KLA/ATP | .95 |
.97 |
1.03 |
1.02 |
1.02 |
1.00 |
.99 |
|
Ptk2b | |
NM_172498 |
PTK2 protein tyrosine kinase 2 beta (Ptk2b), mRNA [NM_172498] |
KLA | 1.34 |
1.39 |
1.78 |
1.70 |
2.36 |
2.26 |
1.77 |
| ATP | 1.08 |
1.21 |
.59 |
.69 |
.65 |
.71 |
1.17 |
| KLA/ATP | 1.41 |
1.55 |
1.07 |
1.33 |
1.07 |
1.24 |
1.80 |
|
Ryr1 | |
AK042482 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630095L05 product:RYANODINE RECEPTOR 1 (SKELETAL MUSCLE-TYPE RYANODINE RECEPTOR) (RYR1) (RYR-1) (SKELETAL MUSCLE CALCIUM RELEASE CHANNEL) homolog [Homo sapiens], full |
KLA | 1.61 |
1.64 |
1.65 |
1.73 |
1.85 |
1.62 |
1.13 |
| ATP | 1.05 |
1.11 |
1.16 |
1.42 |
1.40 |
1.28 |
1.22 |
| KLA/ATP | 1.77 |
1.70 |
1.98 |
2.23 |
1.96 |
1.47 |
1.48 |
|
Ryr1 | |
AK042482 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630095L05 product:RYANODINE RECEPTOR 1 (SKELETAL MUSCLE-TYPE RYANODINE RECEPTOR) (RYR1) (RYR-1) (SKELETAL MUSCLE CALCIUM RELEASE CHANNEL) homolog [Homo sapiens], full i |
KLA | 1.52 |
1.58 |
1.63 |
1.69 |
1.73 |
1.53 |
1.25 |
| ATP | .99 |
.99 |
1.07 |
1.37 |
1.35 |
1.30 |
1.15 |
| KLA/ATP | 1.58 |
1.67 |
1.84 |
1.97 |
1.94 |
1.65 |
1.41 |
|
Ryr1 | |
NM_009109 |
ryanodine receptor 1, skeletal muscle (Ryr1), mRNA [NM_009109] |
KLA | .94 |
.93 |
.89 |
.91 |
.82 |
.86 |
.88 |
| ATP | 1.05 |
.98 |
.95 |
1.08 |
1.41 |
1.28 |
1.15 |
| KLA/ATP | .93 |
.95 |
.92 |
1.02 |
1.62 |
1.96 |
2.06 |
|
Ryr2 | |
BC043140 |
ryanodine receptor 2, cardiac, mRNA (cDNA clone IMAGE:6822493), complete cds. [BC043140] |
KLA | .97 |
1.03 |
1.01 |
1.03 |
1.03 |
1.01 |
1.05 |
| ATP | .99 |
.98 |
1.03 |
1.02 |
1.01 |
1.09 |
1.04 |
| KLA/ATP | .98 |
1.00 |
.98 |
1.04 |
1.04 |
1.06 |
1.00 |
|
Ryr2 | |
NM_023868 |
ryanodine receptor 2, cardiac (Ryr2), mRNA [NM_023868] |
KLA | 1.04 |
1.02 |
1.00 |
1.00 |
1.03 |
.97 |
.96 |
| ATP | .95 |
1.04 |
1.00 |
.94 |
.98 |
1.01 |
1.08 |
| KLA/ATP | .99 |
.97 |
1.02 |
1.03 |
1.00 |
.98 |
1.00 |
|
Ryr3 | |
BC116740 |
ryanodine receptor 3, mRNA (cDNA clone IMAGE:40126059), complete cds. [BC116740] |
KLA | .99 |
.95 |
.96 |
1.08 |
1.04 |
1.01 |
1.02 |
| ATP | 1.06 |
1.02 |
1.00 |
1.03 |
1.01 |
.96 |
1.04 |
| KLA/ATP | 1.06 |
.98 |
.90 |
1.06 |
1.06 |
.97 |
1.06 |
|
Ryr3 | |
NM_177652 |
ryanodine receptor 3 (Ryr3), mRNA [NM_177652] |
KLA | 1.04 |
1.02 |
1.03 |
1.03 |
1.04 |
1.04 |
1.03 |
| ATP | .97 |
.96 |
.99 |
1.06 |
.98 |
1.00 |
1.01 |
| KLA/ATP | 1.03 |
1.02 |
1.01 |
1.03 |
1.02 |
1.02 |
1.01 |
|
Slc25a31
| |
NM_178386 |
solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31 (Slc25a31), nuclear gene encoding mitochondrial protein, mRNA [NM_178386] |
KLA | .99 |
.96 |
.88 |
.97 |
.96 |
.91 |
.75 |
| ATP | 1.09 |
.96 |
.96 |
1.01 |
.92 |
.90 |
.77 |
| KLA/ATP | 1.02 |
.96 |
.89 |
.90 |
.96 |
.93 |
.74 |
|
Slc25a4 | |
NM_007450 |
solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4 (Slc25a4), nuclear gene encoding mitochondrial protein, mRNA [NM_007450] |
KLA | .80 |
.84 |
.85 |
.80 |
.77 |
.70 |
.68 |
| ATP | 1.01 |
1.04 |
.99 |
1.00 |
.81 |
.46 |
.60 |
| KLA/ATP | .88 |
.85 |
.77 |
.78 |
.65 |
.42 |
.23 |
|
Slc25a5 | |
NM_007451 |
solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 5 (Slc25a5), nuclear gene encoding mitochondrial protein, mRNA [NM_007451] |
KLA | .93 |
.93 |
.89 |
.90 |
.93 |
.92 |
1.27 |
| ATP | 1.03 |
1.08 |
.93 |
.97 |
.98 |
.92 |
1.06 |
| KLA/ATP | .84 |
.91 |
.80 |
.87 |
.75 |
.76 |
.55 |
|
Slc8a1 | |
AF004666 |
sodium-calcium exchanger (NCX1) mRNA, complete cds. [AF004666] |
KLA | 1.13 |
1.10 |
1.22 |
1.44 |
1.52 |
1.55 |
1.10 |
| ATP | 1.03 |
1.05 |
1.22 |
1.12 |
.65 |
.49 |
.67 |
| KLA/ATP | 1.04 |
1.21 |
1.30 |
1.44 |
.81 |
.63 |
1.01 |
|
Slc8a1 | |
AF108396 |
sodium/calcium exchanger isoform NaCa3 (Ncx1) mRNA, partial cds. [AF108396] |
KLA | 1.07 |
1.18 |
1.30 |
1.22 |
1.31 |
1.39 |
1.21 |
| ATP | 1.03 |
1.02 |
1.10 |
1.07 |
.88 |
.91 |
1.23 |
| KLA/ATP | 1.15 |
1.17 |
1.14 |
1.22 |
.96 |
1.01 |
1.77 |
|
Slc8a1 | |
NM_011406 |
solute carrier family 8 (sodium/calcium exchanger), member 1 (Slc8a1), transcript variant A, mRNA [NM_011406] |
KLA | 1.12 |
1.16 |
1.22 |
1.25 |
1.35 |
1.33 |
1.11 |
| ATP | 1.03 |
1.04 |
1.07 |
1.10 |
.93 |
.90 |
1.19 |
| KLA/ATP | 1.13 |
1.24 |
1.19 |
1.16 |
.93 |
1.06 |
1.62 |
|
Slc8a2 | |
NM_148946 |
solute carrier family 8 (sodium/calcium exchanger), member 2 (Slc8a2), mRNA [NM_148946] |
KLA | 1.14 |
1.11 |
1.17 |
1.21 |
1.17 |
1.21 |
1.09 |
| ATP | .96 |
.87 |
1.22 |
1.12 |
1.15 |
.96 |
1.01 |
| KLA/ATP | 1.16 |
1.15 |
1.30 |
1.23 |
1.22 |
.95 |
1.00 |
|
Slc8a3 | |
AK139260 |
7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730083B07 product:solute carrier family 8 (sodium [AK139260] |
KLA | .96 |
1.03 |
1.02 |
.95 |
.99 |
1.03 |
.95 |
| ATP | .95 |
.99 |
.98 |
.94 |
1.02 |
.96 |
1.09 |
| KLA/ATP | 1.02 |
.98 |
1.00 |
.88 |
.91 |
.97 |
1.03 |
|
Slc8a3 | |
NM_080440 |
solute carrier family 8 (sodium/calcium exchanger), member 3 (Slc8a3), mRNA [NM_080440] |
KLA | 1.01 |
.99 |
.94 |
1.03 |
.98 |
1.02 |
1.03 |
| ATP | .95 |
1.01 |
1.04 |
.92 |
.95 |
1.00 |
1.05 |
| KLA/ATP | .97 |
.99 |
1.06 |
.97 |
.99 |
.95 |
1.06 |
|
Sphk1 | |
NM_025367 |
sphingosine kinase 1 (Sphk1), transcript variant 2, mRNA [NM_025367] |
KLA | 2.61 |
2.50 |
2.04 |
1.71 |
1.19 |
.91 |
.74 |
| ATP | .94 |
1.00 |
2.06 |
8.09 |
16.52 |
12.59 |
3.53 |
| KLA/ATP | 2.64 |
2.81 |
3.50 |
8.13 |
23.71 |
16.46 |
2.22 |
|
Sphk2 | |
NM_020011 |
sphingosine kinase 2 (Sphk2), transcript variant 2, mRNA [NM_020011] |
KLA | .64 |
.74 |
1.05 |
1.47 |
2.15 |
1.84 |
1.67 |
| ATP | 1.10 |
1.02 |
.57 |
.54 |
.49 |
1.29 |
2.15 |
| KLA/ATP | .78 |
.64 |
.43 |
.56 |
.86 |
1.90 |
3.74 |
|
Stim1 | |
AK086594 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930039F22 product:stromal interaction molecule 1, full insert sequence. [AK086594] |
KLA | .90 |
.98 |
.92 |
.92 |
.97 |
.99 |
.97 |
| ATP | 1.01 |
1.01 |
.91 |
.93 |
.94 |
.98 |
.95 |
| KLA/ATP | .97 |
.92 |
.95 |
.90 |
.94 |
.96 |
.95 |
|
Stim1 | |
NM_009287 |
stromal interaction molecule 1 (Stim1), mRNA [NM_009287] |
KLA | .86 |
.91 |
.72 |
.75 |
.85 |
.86 |
.85 |
| ATP | 1.04 |
1.04 |
.79 |
.71 |
.51 |
.66 |
1.04 |
| KLA/ATP | .92 |
.75 |
.60 |
.65 |
.47 |
.60 |
1.04 |
|
Stim2 | |
NM_001081103 |
stromal interaction molecule 2 (Stim2), mRNA [NM_001081103] |
KLA | 2.06 |
2.23 |
2.06 |
2.17 |
1.47 |
1.12 |
1.54 |
| ATP | 1.07 |
.94 |
1.17 |
1.00 |
1.45 |
2.27 |
1.14 |
| KLA/ATP | 2.15 |
2.37 |
2.63 |
1.58 |
1.57 |
1.47 |
1.55 |
|
Tacr1 | |
NM_009313 |
tachykinin receptor 1 (Tacr1), mRNA [NM_009313] |
KLA | 1.21 |
1.16 |
1.23 |
1.08 |
1.14 |
1.12 |
1.06 |
| ATP | 1.05 |
1.03 |
1.06 |
1.01 |
1.00 |
1.02 |
1.09 |
| KLA/ATP | 1.16 |
1.23 |
1.06 |
1.22 |
1.10 |
1.07 |
1.08 |
|
Tacr2 | |
NM_009314 |
tachykinin receptor 2 (Tacr2), mRNA [NM_009314] |
KLA | 1.04 |
1.13 |
1.11 |
1.14 |
1.12 |
1.11 |
1.06 |
| ATP | 1.02 |
1.00 |
1.01 |
1.03 |
1.05 |
1.10 |
1.01 |
| KLA/ATP | 1.05 |
1.10 |
1.17 |
1.17 |
1.06 |
1.01 |
1.03 |
|
Tacr3 | |
NM_021382 |
tachykinin receptor 3 (Tacr3), mRNA [NM_021382] |
KLA | .97 |
.98 |
1.07 |
1.00 |
1.01 |
1.02 |
.92 |
| ATP | 1.01 |
.99 |
.99 |
1.01 |
1.02 |
1.01 |
1.05 |
| KLA/ATP | 1.03 |
1.00 |
1.02 |
1.01 |
.94 |
1.01 |
1.00 |
|
Tbxa2r | |
NM_009325 |
thromboxane A2 receptor (Tbxa2r), mRNA [NM_009325] |
KLA | 1.02 |
1.02 |
1.03 |
1.01 |
1.01 |
1.02 |
1.05 |
| ATP | .97 |
.98 |
1.03 |
1.09 |
1.06 |
1.09 |
1.01 |
| KLA/ATP | 1.00 |
1.05 |
1.02 |
1.04 |
1.09 |
1.14 |
1.12 |
|
Tnnc1 | |
NM_009393 |
troponin C, cardiac/slow skeletal (Tnnc1), mRNA [NM_009393] |
KLA | .52 |
.57 |
.60 |
.71 |
.91 |
1.03 |
1.71 |
| ATP | .92 |
.70 |
.67 |
.76 |
1.70 |
1.56 |
4.25 |
| KLA/ATP | .57 |
.55 |
.60 |
.66 |
1.03 |
.86 |
2.98 |
|
Tnnc2 | |
NM_009394 |
troponin C2, fast (Tnnc2), mRNA [NM_009394] |
KLA | 1.28 |
1.29 |
1.19 |
1.43 |
1.25 |
1.41 |
1.35 |
| ATP | 1.00 |
.97 |
1.05 |
1.26 |
1.38 |
1.19 |
1.08 |
| KLA/ATP | 1.21 |
1.24 |
1.35 |
1.38 |
2.06 |
1.52 |
1.39 |
|
Trhr | |
NM_013696 |
thyrotropin releasing hormone receptor (Trhr), mRNA [NM_013696] |
KLA | 1.02 |
1.02 |
1.03 |
1.02 |
.97 |
.96 |
.95 |
| ATP | 1.07 |
.94 |
.98 |
1.01 |
.99 |
.99 |
.96 |
| KLA/ATP | 1.02 |
.99 |
.99 |
1.00 |
.99 |
.94 |
.94 |
|
Trhr2 | |
NM_133202 |
thyrotropin releasing hormone receptor 2 (Trhr2), mRNA [NM_133202] |
KLA | .99 |
1.01 |
1.00 |
1.02 |
.98 |
1.07 |
1.08 |
| ATP | .96 |
1.02 |
1.01 |
1.02 |
.95 |
.97 |
.98 |
| KLA/ATP | 1.01 |
.96 |
1.00 |
1.04 |
.97 |
1.00 |
.97 |
|
Vdac1 | |
NM_011694 |
voltage-dependent anion channel 1 (Vdac1), mRNA [NM_011694] |
KLA | .85 |
.86 |
.95 |
.80 |
.69 |
.62 |
.76 |
| ATP | .93 |
1.01 |
1.32 |
1.01 |
.96 |
.82 |
.57 |
| KLA/ATP | .81 |
.85 |
1.05 |
.78 |
.78 |
.78 |
.48 |
|
Vdac2 | |
NM_011695 |
voltage-dependent anion channel 2 (Vdac2), mRNA [NM_011695] |
KLA | .92 |
.89 |
.80 |
.96 |
.85 |
.97 |
.83 |
| ATP | .84 |
.72 |
.75 |
.54 |
.52 |
.48 |
.72 |
| KLA/ATP | .74 |
.68 |
.71 |
.48 |
.69 |
.59 |
.37 |
|
Vdac3 | |
NM_011696 |
voltage-dependent anion channel 3 (Vdac3), mRNA [NM_011696] |
KLA | 1.09 |
1.11 |
1.13 |
1.15 |
1.12 |
1.21 |
1.45 |
| ATP | .95 |
.96 |
1.06 |
.91 |
.91 |
1.36 |
1.11 |
| KLA/ATP | 1.06 |
1.06 |
1.20 |
1.03 |
1.11 |
1.07 |
1.12 |
|